[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 488
1. Buckton-Tucker R: How a Brain Tumour took over my Life: Diagnosis and removal of a benign meningioma. Sultan Qaboos Univ Med J; 2009 Aug;9(2):198-200

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How a Brain Tumour took over my Life: Diagnosis and removal of a benign meningioma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21509301.001).
  • [ISSN] 2075-0528
  • [Journal-full-title] Sultan Qaboos University medical journal
  • [ISO-abbreviation] Sultan Qaboos Univ Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Oman
  • [Other-IDs] NLM/ PMC3074780
  •  go-up   go-down


2. Baser ME, Poussaint TY: Age associated increase in the prevalence of chromosome 22q loss of heterozygosity in histological subsets of benign meningioma. J Med Genet; 2006 Mar;43(3):285-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age associated increase in the prevalence of chromosome 22q loss of heterozygosity in histological subsets of benign meningioma.
  • Chromosome 22q loss of heterozygosity (LOH) is the most common allelic loss in benign meningioma and is thought to be the earliest initiating event in meningioma formation.
  • We used published data and logistic regression to evaluate the association of 22q LOH with age at diagnosis in 318 transitional, fibroblastic, and meningothelial meningiomas.
  • After adjustment for anatomical location, the odds ratio of 22q LOH per year of age was >1 in each histological type of meningioma, and was significantly >1 in transitional and fibroblastic meningioma.
  • This finding is compatible with involvement of the neurofibromatosis 2 tumour suppressor gene, NF2, on chromosome 22q in the high incidence of benign meningioma in the elderly.
  • [MeSH-major] Chromosomes, Human, Pair 22. Loss of Heterozygosity. Meningeal Neoplasms / genetics. Meningioma / genetics. Neurofibromin 2 / genetics

  • Genetic Alliance. consumer health - Chromosome 22q.
  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2002 Jun;282(6):G932-6 [12016117.001]
  • [Cites] J Pathol. 2001 Jul;194(3):367-72 [11439370.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):5863-7 [2393856.001]
  • [Cites] Cell. 1993 Mar 12;72(5):791-800 [8453669.001]
  • [Cites] Nature. 1993 Jun 10;363(6429):515-21 [8379998.001]
  • [Cites] Nat Genet. 1994 Feb;6(2):180-4 [8162072.001]
  • [Cites] Hum Mol Genet. 1994 Jun;3(6):885-91 [7951231.001]
  • [Cites] Hum Mol Genet. 1994 Aug;3(8):1393-9 [7987321.001]
  • [Cites] Hum Genet. 1995 Mar;95(3):347-51 [7868131.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Mar;54(2):224-35 [7876890.001]
  • [Cites] Am J Pathol. 1995 Apr;146(4):827-32 [7717450.001]
  • [Cites] Oncogene. 1995 Apr 20;10(8):1521-8 [7731706.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Jul;13(3):211-6 [7669741.001]
  • [Cites] Neurosurgery. 1995 Oct;37(4):764-73 [8559307.001]
  • [Cites] Neurosurgery. 1997 Mar;40(3):578-87 [9055299.001]
  • [Cites] Acta Neuropathol. 1997 Mar;93(3):225-32 [9083553.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Dec;20(4):419-24 [9408760.001]
  • [Cites] Lab Invest. 1997 Dec;77(6):601-6 [9426397.001]
  • [Cites] J Neurosurg. 1998 May;88(5):831-9 [9576250.001]
  • [Cites] J Neurooncol. 1998 Nov;40(2):101-6 [9892091.001]
  • [Cites] Oncogene. 1999 Apr 1;18(13):2231-9 [10327069.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Apr;64(4):312-22 [15835267.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Oct 15;162(2):135-9 [16213361.001]
  • [Cites] Hum Mutat. 2006 Apr;27(4):297-306 [16521120.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Oct;59(10):872-9 [11079777.001]
  • [Cites] Cancer Res. 1999 Dec 1;59(23):5995-8 [10606247.001]
  • [Cites] Neurology. 2000 Jan 11;54(1):71-6 [10636128.001]
  • [Cites] Hum Mol Genet. 2000 Jun 12;9(10):1495-500 [10888600.001]
  • [Cites] J Neurosurg. 2001 Jan;94(1):111-7 [11147878.001]
  • [Cites] Br J Cancer. 2001 Jan;84(2):199-201 [11161377.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1208-12 [15022288.001]
  • (PMID = 15980114.001).
  • [ISSN] 1468-6244
  • [Journal-full-title] Journal of medical genetics
  • [ISO-abbreviation] J. Med. Genet.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neurofibromin 2
  • [Other-IDs] NLM/ PMC2563234
  •  go-up   go-down


3. Rao S, Rajkumar A, Kuruvilla S: Angiomatous meningioma: a diagnostic dilemma. Indian J Pathol Microbiol; 2008 Jan-Mar;51(1):53-5
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiomatous meningioma: a diagnostic dilemma.
  • Angiomatous meningioma accounts for 2.1% of all meningiomas.
  • It has features of a typical benign meningioma with many small or large vascular channels which may predominate over its meningothelial elements.
  • We present here a series of three cases of angiomatous meningioma, which posed diagnostic difficulty to clinicians, radiologists, and pathologists.
  • We present series of three cases to highlight the histomorphological features of this uncommon variant of meningioma that could help in distinguishing it from hemangioblastoma and hemangiopericytoma.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18417856.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


Advertisement
4. James MF, Lelke JM, Maccollin M, Plotkin SR, Stemmer-Rachamimov AO, Ramesh V, Gusella JF: Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth. Neurobiol Dis; 2008 Feb;29(2):278-92
Hazardous Substances Data Bank. BROMODEOXYURIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth.
  • Meningiomas, common tumors arising from arachnoidal cells of the meninges, may occur sporadically, or in association with the inherited disorder, neurofibromatosis 2 (NF2).
  • Most sporadic meningiomas result from NF2 inactivation, resulting in loss of tumor suppressor merlin, implicated in regulating membrane-cytoskeletal organization.
  • To investigate merlin function in an authentic target cell type for NF2 tumor formation, we established primary cultures from genetically-matched meningioma and normal arachnoidal tissues.
  • Our studies revealed novel and distinct cell biological and biochemical properties unique to merlin-deficient meningioma cells compared to merlin-expressing arachnoidal and meningioma cells, and other NF2-deficient cell types.
  • Merlin-deficient meningioma cells displayed cytoskeletal and cell contact defects, altered cell morphology and growth properties, most notably cell senescence, implicating the activation of senescence pathways in limiting benign meningioma growth.
  • Merlin suppression by RNAi in arachnoidal cells replicated merlin-deficient meningioma features, thus establishing these cell systems as disease-relevant models for studying NF2 tumorigenesis.

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1998 Oct 29;17(17):2195-209 [9811451.001]
  • [Cites] Neurobiol Dis. 1998 Jul;5(1):55-64 [9702788.001]
  • [Cites] Oncogene. 1999 Aug 26;18(34):4788-97 [10490812.001]
  • [Cites] J Virol Methods. 2004 Dec 15;122(2):131-9 [15542136.001]
  • [Cites] Oncogene. 2004 Nov 18;23(54):8815-25 [15467741.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] Int J Biochem Cell Biol. 2005 May;37(5):961-76 [15743671.001]
  • [Cites] Mol Cell Biol. 2005 Mar;25(6):2384-94 [15743831.001]
  • [Cites] Neurobiol Dis. 2005 Jun-Jul;19(1-2):1-9 [15837555.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):642 [16079833.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):725-30 [16079851.001]
  • [Cites] Br J Neurosurg. 2005 Feb;19(1):5-12 [16147576.001]
  • [Cites] Genes Dev. 2005 Oct 1;19(19):2265-77 [16204178.001]
  • [Cites] J Cell Biol. 2005 Oct 24;171(2):361-71 [16247032.001]
  • [Cites] J Neurosci. 2006 Mar 29;26(13):3390-5 [16571745.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):459-72 [17157787.001]
  • [Cites] J Biol Chem. 1999 Dec 3;274(49):34507-10 [10574907.001]
  • [Cites] Cancer. 1999 Dec 15;86(12):2649-58 [10594860.001]
  • [Cites] Cell. 2000 Jan 21;100(2):209-19 [10660044.001]
  • [Cites] Neurology. 2000 Mar 14;54(5):1132-8 [10720287.001]
  • [Cites] Neuropathol Appl Neurobiol. 2001 Feb;27(1):40-9 [11299001.001]
  • [Cites] Genes Dev. 2001 Apr 15;15(8):968-80 [11316791.001]
  • [Cites] Biochim Biophys Acta. 2001;1471(2):M73-80 [11342186.001]
  • [Cites] Dev Cell. 2001 Jul;1(1):63-72 [11703924.001]
  • [Cites] J Cell Sci. 2001 Oct;114(Pt 20):3583-90 [11707510.001]
  • [Cites] Mol Cell Biol. 2002 Feb;22(4):1150-7 [11809806.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Genes Dev. 2002 May 1;16(9):1060-5 [12000789.001]
  • [Cites] Neoplasia. 2002 Jul-Aug;4(4):279-90 [12082543.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Aug;3(8):586-99 [12154370.001]
  • [Cites] Oncogene. 2002 Sep 5;21(39):5990-7 [12203111.001]
  • [Cites] J Cell Sci. 2002 Nov 1;115(Pt 21):3991-4000 [12356905.001]
  • [Cites] Int J Cancer. 2003 Feb 10;103(4):483-8 [12478663.001]
  • [Cites] RNA. 2003 Apr;9(4):493-501 [12649500.001]
  • [Cites] Genes Dev. 2003 May 1;17(9):1090-100 [12695331.001]
  • [Cites] Hum Mol Genet. 2003 Jun 1;12(11):1211-21 [12761036.001]
  • [Cites] Mol Biol Cell. 2003 May;14(5):2181-91 [12802084.001]
  • [Cites] Int J Mol Med. 2003 Dec;12(6):943-7 [14612971.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Apr;63(4):275-86 [15099018.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2004 Jun;75 Suppl 2:ii2-11 [15146033.001]
  • [Cites] J Cell Sci. 2004 Jun 15;117(Pt 14):2951-61 [15161943.001]
  • [Cites] Exp Cell Res. 1983 Jul;146(2):371-6 [6192005.001]
  • [Cites] Lab Invest. 1986 Jul;55(1):71-85 [3724065.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Aug;84(15):5419-23 [3037550.001]
  • [Cites] Cell. 1992 Aug 7;70(3):401-10 [1643658.001]
  • [Cites] Cell. 1993 Mar 12;72(5):791-800 [8453669.001]
  • [Cites] Histopathology. 1993 Feb;22(2):113-25 [7681027.001]
  • [Cites] Nature. 1993 Jun 10;363(6429):515-21 [8379998.001]
  • [Cites] Neurosci Lett. 1994 Jan 3;165(1-2):122-4 [8015711.001]
  • [Cites] Cancer Res. 1995 Jun 1;55(11):2270-4 [7757975.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7 [7568133.001]
  • [Cites] J Cell Biol. 1996 May;133(4):843-52 [8666669.001]
  • [Cites] Oncogene. 1996 Sep 19;13(6):1239-47 [8808698.001]
  • [Cites] Genes Chromosomes Cancer. 1996 Sep;17(1):45-55 [8889506.001]
  • [Cites] JAMA. 1997 Jul 2;278(1):51-7 [9207339.001]
  • [Cites] J Cell Biol. 1997 Aug 25;138(4):913-26 [9265656.001]
  • [Cites] Science. 1998 Jan 23;279(5350):509-14 [9438836.001]
  • [Cites] J Biol Chem. 1998 Mar 27;273(13):7757-64 [9516485.001]
  • [Cites] Genes Dev. 1998 Apr 15;12(8):1121-33 [9553042.001]
  • [Cites] Hum Mol Genet. 1999 Feb;8(2):267-75 [9931334.001]
  • (PMID = 17962031.001).
  • [ISSN] 0969-9961
  • [Journal-full-title] Neurobiology of disease
  • [ISO-abbreviation] Neurobiol. Dis.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / P30 NS045776-04; United States / NINDS NIH HHS / NS / NS024279-15A10010; United States / NINDS NIH HHS / NS / P01 NS024279-130001; United States / NINDS NIH HHS / NS / NS024279-160010; United States / NINDS NIH HHS / NS / P30 NS045776-03; United States / NINDS NIH HHS / NS / NS045776; United States / NINDS NIH HHS / NS / NS045776-05; United States / NINDS NIH HHS / NS / NS045776-019003; United States / NINDS NIH HHS / NS / NS045776-01; United States / NINDS NIH HHS / NS / NS024279-140001; United States / NINDS NIH HHS / NS / NS041917-04; United States / NINDS NIH HHS / NS / P30 NS045776; United States / NINDS NIH HHS / NS / P30 NS045776-019001; United States / NINDS NIH HHS / NS / NS024279; United States / NINDS NIH HHS / NS / NS024279-130001; United States / NINDS NIH HHS / NS / NS041917-02; United States / NINDS NIH HHS / NS / R01 NS041917; United States / NINDS NIH HHS / NS / R01 NS041917-05; United States / NINDS NIH HHS / NS / R01 NS041917-02; United States / NINDS NIH HHS / NS / NS045776-04; United States / NINDS NIH HHS / NS / P01 NS024279-15A10010; United States / NINDS NIH HHS / NS / NS024279-120001; United States / NINDS NIH HHS / NS / NS041917-05; United States / NINDS NIH HHS / NS / P30 NS045776-01; United States / NINDS NIH HHS / NS / NS041917-03; United States / NINDS NIH HHS / NS / P01 NS024279-120001; United States / NINDS NIH HHS / NS / P30 NS045776-019003; United States / NINDS NIH HHS / NS / NS045776-03; United States / NINDS NIH HHS / NS / P30 NS045776-02; United States / NINDS NIH HHS / NS / P30 NS045776-05; United States / NINDS NIH HHS / NS / P01 NS024279; United States / NINDS NIH HHS / NS / R01 NS041917-01; United States / NINDS NIH HHS / NS / NS041917-01; United States / NINDS NIH HHS / NS / R01 NS041917-04; United States / NINDS NIH HHS / NS / NS045776-019001; United States / NINDS NIH HHS / NS / P01 NS024279-140001; United States / NINDS NIH HHS / NS / NS041917; United States / NINDS NIH HHS / NS / R01 NS041917-03; United States / NINDS NIH HHS / NS / P01 NS024279-160010
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Catenins; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / Neurofibromin 2; 0 / RNA, Small Interfering; G34N38R2N1 / Bromodeoxyuridine
  • [Other-IDs] NLM/ NIHMS39296; NLM/ PMC2266821
  •  go-up   go-down


5. Nasseri K, Mills JR: Epidemiology of primary brain tumors in the Middle Eastern population in California, USA 2001-2005. Cancer Detect Prev; 2009;32(5-6):363-71
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Data for 683 cases of primary brain tumors (429 benign, 238 malignant, 16 uncertain) in the ME and 15,589 cases (8352 benign, 6812 malignant, 425 uncertain) in the NHNMW were available for this study.
  • RESULTS: ME patients were significantly (p < 0.05) younger and their age-adjusted incidence rates per 100,000 for benign tumors of 10.0 in men and 17.6 in women were higher than similar rates of 7.3 and 10.6 in the NHNMW group (p < 0.05).
  • Meningioma was the main histology responsible for the observed increase in patients over 40 years of age.
  • Also increased were benign tumors of the pituitary and pineal glands.
  • The overall mortality in patients with benign tumors was significantly lower than malignant tumors.
  • CONCLUSIONS: This study presents a significantly high incidence of benign meningioma in the ME population in California.
  • Considering the reported causal association of benign meningioma with childhood radiation exposure from Israel, exposure to this risk factor in this ethnic group needs to be evaluated in future studies.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2005 Dec 15;104(12):2798-806 [16288487.001]
  • [Cites] Radiat Res. 2005 Apr;163(4):424-32 [15799699.001]
  • [Cites] Calif Med. 1949 Mar;70(3):189-93 [18112454.001]
  • [Cites] Asian Pac J Cancer Prev. 2007 Jul-Sep;8(3):405-11 [18159978.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Apr;105(4):470-80 [18206397.001]
  • [Cites] Cancer Causes Control. 2008 Dec;19(10):1183-91 [18543070.001]
  • [Cites] Am J Epidemiol. 2000 Feb 1;151(3):266-72 [10670551.001]
  • [Cites] Dermatol Surg. 2001 Jul;27(7):667-9 [11442620.001]
  • [Cites] Neuro Oncol. 1999 Jul;1(3):205-11 [11554389.001]
  • [Cites] Neoplasma. 2001;48(6):442-4 [11949834.001]
  • [Cites] Neuro Oncol. 2002 Oct;4(4):278-99 [12356358.001]
  • [Cites] Cancer Detect Prev. 2003;27(3):203-8 [12787727.001]
  • [Cites] Br J Surg. 1977 Jul;64(7):457-9 [922301.001]
  • [Cites] Neuroepidemiology. 1989;8(6):283-95 [2586698.001]
  • [Cites] Health Inf Manag. 1997 Mar-May;27(1):31-8 [10169442.001]
  • [Cites] Cancer Detect Prev. 2007;31(5):424-9 [18023539.001]
  • (PMID = 19588542.001).
  • [ISSN] 1525-1500
  • [Journal-full-title] Cancer detection and prevention
  • [ISO-abbreviation] Cancer Detect. Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA103457-02; United States / NCI NIH HHS / CA / CA103457; United States / NCI NIH HHS / PC / N01-PC-35139; United States / NCCDPHP CDC HHS / DP / U58 DP000807; United States / NCI NIH HHS / CA / N01PC54404; United States / NCI NIH HHS / CA / R03 CA103457-02; United States / NCI NIH HHS / CA / R03 CA103457; United States / NCI NIH HHS / CA / N01PC35136; United States / NCI NIH HHS / CA / N01PC35139; United States / NCI NIH HHS / PC / N01-PC-54404; United States / NCI NIH HHS / PC / N01-PC-35136; United States / NCCDPHP CDC HHS / DP / 1U58DP00807-01
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS140088; NLM/ PMC2785228
  •  go-up   go-down


6. Monleón D, Morales JM, Gonzalez-Segura A, Gonzalez-Darder JM, Gil-Benso R, Cerdá-Nicolás M, López-Ginés C: Metabolic aggressiveness in benign meningiomas with chromosomal instabilities. Cancer Res; 2010 Nov 1;70(21):8426-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolic aggressiveness in benign meningiomas with chromosomal instabilities.
  • Meningiomas are often considered benign tumors curable by surgery, but most recurrent meningiomas correspond to histologic benign tumors.
  • The aim of this study was to achieve higher specificity in the detection of meningioma subgroups by measuring chromosomal instabilities by fluorescence in situ hybridization and cytogenetics and metabolic phenotypes by high-resolution magic angle spinning spectroscopy.
  • We studied 46 meningioma biopsies with these methodologies.
  • Of these, 34 were of WHO grade 1 and 12 were of WHO grade 2.
  • Genetic analysis showed a subgroup of histologic benign meningioma with chromosomal instabilities.
  • The metabolic phenotype of this subgroup indicated an aggressive metabolism resembling that observed for atypical meningioma.
  • Taken together, our results identify distinct metabolic phenotypes for otherwise benign meningiomas based on cytogenetic studies and global metabolic profiles of intact tumors.
  • Measuring the metabolic phenotype of meningioma intact biopsies at the same time as histopathologic analysis may allow the early detection of clinically aggressive tumors.
  • [MeSH-major] Chromosomal Instability. Chromosome Aberrations. Meningeal Neoplasms / genetics. Meningioma / genetics. Metabolome / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • (PMID = 20861191.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


7. Püttmann S, Senner V, Braune S, Hillmann B, Exeler R, Rickert CH, Paulus W: Establishment of a benign meningioma cell line by hTERT-mediated immortalization. Lab Invest; 2005 Sep;85(9):1163-71
Cellosaurus - a cell line knowledge resource. culture/stock collections - Ben-Men-1 (CVCL_1959) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment of a benign meningioma cell line by hTERT-mediated immortalization.
  • Meningioma represents the most common intracranial tumor, but well-characterized cell lines derived from benign meningiomas are not available.
  • A major reason for the lack of benign tumor cell lines is senescence of nonmalignant cells in vitro, while malignant cells are often immortal.
  • We have developed a meningioma cell line by retrovirally transducing primary cells derived from a human WHO grade I meningothelial meningioma with the human telomerase reverse transcriptase (hTERT) gene, which enables bypassing cellular senescence.
  • One clone, designated Ben-Men-1, was characterized in more detail, and exhibited typical cytological, immunocytochemical, ultrastructural and genetical features of meningioma, including whorl formation, expression of epithelial membrane antigen, desmosomes and interdigitating cell processes, as well as -22q.
  • Following subdural transplantation into nude mice, tumor tissue with typical histological features of meningothelial meningioma was found.
  • We conclude that Ben-Men-1 represents an immortalized yet differentiated cell line useful for biological and therapeutical studies on meningioma.
  • [MeSH-major] Cell Transformation, Neoplastic / genetics. DNA-Binding Proteins / genetics. Meningioma / pathology. Telomerase / genetics

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15965488.001).
  • [ISSN] 0023-6837
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


8. Colombo F, Casentini L, Cavedon C, Scalchi P, Cora S, Francescon P: Cyberknife Radiosurgery for Benign Meningiomas: Short-term Results in 199 Patients. Neurosurgery; 2009 Feb 01;64(suppl_2):A7-A13

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyberknife Radiosurgery for Benign Meningiomas: Short-term Results in 199 Patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28173326.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Kwon Y, Bae JS, Kim JM, Lee DH, Kim SY, Ahn JS, Kim JH, Kim CJ, Kwun BD, Lee JK: Visual changes after gamma knife surgery for optic nerve tumors. J Neurosurg; 2005 Jan;102(s_supplement):143-146

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ✓ Tumors involving the optic nerve (optic glioma, optic nerve sheath meningioma) are benign but difficult to treat.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28306473.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; gamma knife surgery / optic glioma / optic nerve sheath meningioma
  •  go-up   go-down


10. Tlachacova D, Schmitt M, Novotny J Jr, Novotny J, Majali M, Liscak R: A comparison of the gamma knife model C and the Automatic Positioning System with Leksell model B. J Neurosurg; 2005 Jan;102(s_supplement):25-28
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Data were analyzed in patients in whom the following diagnoses had been made: vestibular schwannoma, pituitary adenoma, meningioma, solitary metastasis, and other benign and malignant solitary tumors.
  • CONCLUSIONS: With the C model there was a better conformity for most treated targets, such as vestibular schwannomas (p = 0.005) and meningiomas (p = 0.015).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28306471.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; conformity index / extracranial exposure / staff exposure / stereotactic radiosurgery
  •  go-up   go-down


11. Velnar T, Bunc G: Iatrogenic metastasis of a benign meningioma to the periosteum at the site of previous craniotomy: a case report. Wien Klin Wochenschr; 2008;120(23-24):766-9
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Iatrogenic metastasis of a benign meningioma to the periosteum at the site of previous craniotomy: a case report.
  • Metastasis formation after resection of meningiomas is a rare event, predominantly occurring with malignant phenotypes.
  • As far as we know, the presented case is the first report in the literature of iatrogenic seeding of a benign meningioma to the scalp following surgery.
  • A 37-year-old woman was admitted because of a relapsing meningioma in the frontal lobe.
  • In 1997, she had undergone complete excision of an atypical meningioma in same location.
  • At follow-up, three new masses were found: a bifrontal meningioma on the edge of the falx, a smaller one in the falx just under the saggital sinus and a small mass, believed to be ectopic, in the periosteum at the site of the previous craniotomy.
  • Histologically, the ectopic tumor was an atypical meningioma, similar to the one excised 10 years previously, with no relation to the other two intracranial masses.
  • The authors suggest that strict adherence to oncological principles should be applied in the case of benign neoplasms in order to prevent contamination of wounds with tumor cells and potential recurrence.
  • [MeSH-major] Craniotomy. Meningeal Neoplasms / surgery. Meningioma / secondary. Meningioma / surgery. Neoplasm Seeding. Neoplasms, Multiple Primary / surgery. Periosteum. Skull Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 2002 Sep;97(3):683-6 [12296654.001]
  • [Cites] Virchows Arch. 2001 Aug;439(2):196-200 [11561761.001]
  • [Cites] Br J Neurosurg. 1994;8(1):93-5 [8011202.001]
  • [Cites] Wien Klin Wochenschr. 1990 Sep 28;102(18):525-8 [2264343.001]
  • [Cites] Neurol Med Chir (Tokyo). 2004 Nov;44(11):600-2 [15686181.001]
  • [Cites] Wien Klin Wochenschr. 1975 Sep 19;87(17):560-3 [1189455.001]
  • [Cites] Neurol India. 2000 Mar;48(1):94-5 [10751830.001]
  • [Cites] Neurol Med Chir (Tokyo). 1993 Jul;33(7):458-62 [7692324.001]
  • [Cites] Virchows Arch. 2001 Mar;438(3):316-8 [11315631.001]
  • [Cites] Neurosurg Rev. 1998;21(4):295-8 [10068194.001]
  • [Cites] Oncology. 2002;62(4):386-8 [12138248.001]
  • [Cites] Br J Neurosurg. 2004 Aug;18(4):357-61 [15702834.001]
  • [Cites] Neurol Med Chir (Tokyo). 2007 Jan;47(1):36-9 [17245014.001]
  • (PMID = 19122989.001).
  • [ISSN] 0043-5325
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


12. Kollová A, Liscák R, Novotný J Jr, Vladyka V, Simonová G, Janousková L: Gamma Knife surgery for benign meningioma. J Neurosurg; 2007 Aug;107(2):325-36
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma Knife surgery for benign meningioma.
  • OBJECT: Meningioma is the most frequent benign tumor treated with Gamma Knife surgery (GKS); however, the assessment of its efficacy and safety in slow-growing tumors is an ongoing process, requiring analysis of long-term results.
  • METHODS: Three hundred sixty-eight patients harboring 400 meningiomas treated between 1992 and 1999 at Na Homolce Hospital were evaluated.
  • CONCLUSIONS: Stereotactic radiosurgery is a safe method of treatment for meningiomas.
  • A minimum margin dose of 12 to 16 Gy seems to represent the therapeutic window for benign meningiomas with a high tumor control rate in a mid-term follow-up period.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / pathology. Meningioma / surgery. Radiosurgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17695387.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Psaras T, Pantazis G, Steger V, Meyermann R, Honegger J, Beschorner R: Benign meningioma developing late lung metastases: case report and review of the literature. Clin Neuropathol; 2009 Nov-Dec;28(6):453-9
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for benign meningioma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign meningioma developing late lung metastases: case report and review of the literature.
  • Here we report the case of a 65-year-old female with a histologically benign parietal falcine meningioma who developed multiple lung metastases 15 years after tumor resection.
  • The meningioma was initially incompletely resected due to invasion of the sagittal sinus.
  • Since it was diagnosed as a benign meningothelial meningioma Grade I WHO, the residual tumor was followed with serial imaging without adjuvant treatment.
  • The lung lesions were successfully removed surgically and histologically diagnosed as meningothelial meningioma Grade I WHO.
  • A repeat brain MRI revealed the known residual meningioma with no signs of interval tumor growth, but did demonstrate occlusion of the sagittal sinus.
  • In the further course, the residual meningioma was completely removed.
  • A review of the literature revealed only 15 well-documented cases of benign meningiomas that metastasized in an interval of up to 12 years after primary tumor resection.
  • This case illustrates that histologically benign meningiomas Grade I WHO with stable disease of the primary tumor have the potential to develop hematogenous metastases even after a long time interval.
  • [MeSH-major] Lung Neoplasms / secondary. Meningeal Neoplasms / pathology. Meningioma / secondary

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19919820.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 25
  •  go-up   go-down


14. Kunert P, Matyja E, Janowski M, Marchel A: Rapid growth of small, asymptomatic meningioma following radiosurgery. Br J Neurosurg; 2009 Apr;23(2):206-8
MedlinePlus Health Information. consumer health - After Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid growth of small, asymptomatic meningioma following radiosurgery.
  • The authors present the case of a 62-year-old woman with rapid enlargement of a meningioma following radiosurgery (RS).
  • Previous slow growth of the tumor over a 3-year period and the radiological signs of benign meningioma had been confirmed by successive MR scans.
  • Histopathological examination performed after successful surgical removal revealed an atypical, infiltrating meningioma.
  • [MeSH-major] Meningeal Neoplasms. Meningioma. Postoperative Complications / surgery

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19306181.001).
  • [ISSN] 1360-046X
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. Mandal S, Dhingra K, Gupta P, Khurana N: Rare growth of a psammomatous meningioma in a mature ovarian teratoma: a case report. Pathol Res Pract; 2010 May 15;206(5):322-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare growth of a psammomatous meningioma in a mature ovarian teratoma: a case report.
  • The presence of meningothelial elements along with abundant psammoma bodies indicates the presence of a benign meningioma within a teratoma.
  • Recognition of meningioma arising in the setting of a teratoma is of prognostic significance, depending on the nature of this component and its spread beyond the organ of origin.
  • We report a case of psammomatous meningioma in which meningothelial cells and psammoma bodies were both abundant and diffuse, allowing for the diagnosis of a meningioma.
  • [MeSH-major] Meningioma / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology. Teratoma / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Elsevier GmbH. All rights reserved.
  • (PMID = 19616897.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Swinnen LJ, Rankin C, Rushing EJ, Laura HF, Damek DM, Barger GR: Phase II study of hydroxyurea for unresectable meningioma (Southwest Oncology Group S9811). J Clin Oncol; 2009 May 20;27(15_suppl):2063

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of hydroxyurea for unresectable meningioma (Southwest Oncology Group S9811).
  • : 2063 Background: Meningiomas account for 15%-18% of CNS tumors.
  • Although benign, recurrence is seen in 16%-39% of cases, depending on the extent of resection possible.
  • Induction of apoptosis was furthermore demonstrated with HU in primary benign meningioma explant cultures.
  • The S9811 phase II trial was undertaken to estimate the objective response rate, if any, of unresectable benign meningioma to this HU regimen.
  • METHODS: Eligibility required unresectable, measurable, residual or recurrent, histologically-proven benign meningioma.
  • Toxicity was mainly hematologic: 11/28 (39%) grade 3, 2/28 (11%) grade 4.
  • Grade 3 non-hematologic toxicity was seen in 7/28 (25%).
  • CONCLUSIONS: Chronic HU therapy for unresectable benign meningioma resulted in an estimated objective response rate of < 12%.
  • Whether the stable disease rate seen differs in any way from what can be expected from the natural history of meningioma cannot be determined from this phase II study design.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964694.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Noël G, Bollet MA, Calugaru V, Feuvret L, Haie-Meder C, Dhermain F, Ferrand R, Boisserie G, Beaudré A, Mazeron JJ, Habrand JL: Functional outcome of patients with benign meningioma treated by 3D conformal irradiation with a combination of photons and protons. Int J Radiat Oncol Biol Phys; 2005 Aug 1;62(5):1412-22
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional outcome of patients with benign meningioma treated by 3D conformal irradiation with a combination of photons and protons.
  • PURPOSE: To evaluate efficacy and tolerance of external fractionated combination of photon and proton radiation therapy (RT) for intracranial benign meningiomas.
  • METHODS AND MATERIALS: Between 1994 and 2002, 51 patients with intracranial meningiomas of the base of the skull were treated with a combination of photon and proton RT.
  • Pathology revealed a malignant (Grade 3) transformation of the initial Grade 1 meningioma.
  • Two patients complained of Grade 3 side effects: 1 unilateral hearing loss requiring aid and 1 case of complete pituitary deficiency.
  • CONCLUSION: These results stressed the clinical efficacy of fractionated-associated photon-proton RT in the treatment of meningiomas, especially on cranial nerve palsies, without severe toxicity in almost all patients.
  • [MeSH-major] Meningeal Neoplasms / radiotherapy. Meningioma / radiotherapy. Photons / therapeutic use. Protons / therapeutic use. Radiotherapy, Conformal / methods. Visual Acuity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029801.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons
  •  go-up   go-down


18. Ren G, Chen S, Wang Y, Zhu RJ, Geng DY, Feng XY: Quantitative evaluation of benign meningioma and hemangiopericytoma with peritumoral brain edema by 64-slice CT perfusion imaging. Chin Med J (Engl); 2010 Aug 5;123(15):2038-44
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative evaluation of benign meningioma and hemangiopericytoma with peritumoral brain edema by 64-slice CT perfusion imaging.
  • BACKGROUND: Hemangiopericytomas (HPCs) have a relentless tendency for local recurrence and metastases, differentiating between benign meningiomas and HPCs before surgery is important for both treatment planning and the prognosis appraisal.
  • The purpose of this study was to evaluate the correlations between CT perfusion parameters and microvessel density (MVD) in extra-axial tumors and the possible role of CT perfusion imaging in preoperatively differentiating benign meningiomas and HPCs.
  • METHODS: Seventeen patients with benign meningiomas and peritumoral edema, 12 patients with HPCs and peritumoral edema underwent 64-slice CT perfusion imaging pre-operation.
  • The quantitative parameters, include cerebral blood volume (CBV), permeability surface (PS) of parenchyma, peritumoral edema among benign meningiomas and HPCs were compared respectively.
  • CBV and PS in parenchyma, peritumoral edema of benign meningiomas and HPCs were also compared to that of the contrallateral normal white matter respectively.
  • RESULTS: The value of CBV and PS in parenchyma of HPCs were significantly higher than that of benign meningiomas (P < 0.05), while the values of CBV and PS in peritumoral edema of benign meningiomas and HPCs were not significantly different (P > 0.05).
  • MVD in parenchyma of HPCs were significantly higher than that of benign meningiomas (P < 0.05).
  • Furthermore, the value of CBV and PS in parenchyma of benign meningiomas and HPCs were significantly higher than that of contrallateral normal white matter (P < 0.05), the value of CBV in peritumoral edema of benign meningiomas and HPCs were significantly lower than that of contrallateral normal white matter (P < 0.05), while the value of PS in peritumoral edema of benign meningiomas and HPCs were not significantly different with that of contrallateral normal white matter (P > 0.05).
  • CONCLUSIONS: CT perfusion imaging can provide critical information on the vascularity of HPC and benign meningiomas.
  • Determination of maximal CBV and corresponding PS values in the parenchyma may be useful in the preoperative differentiating HPC from benign meningiomas.
  • [MeSH-major] Hemangiopericytoma / diagnosis. Meningioma / diagnosis. Tomography, X-Ray Computed / methods


19. Fulkerson DH, Horner TG, Hattab EM: Histologically benign intraventricular meningioma with concurrent pulmonary metastasis: case report and review of the literature. Clin Neurol Neurosurg; 2008 Apr;110(4):416-9
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for intraventricular meningioma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologically benign intraventricular meningioma with concurrent pulmonary metastasis: case report and review of the literature.
  • Only 1-2% of all meningiomas are intraventricular in location.
  • Metastasis from a histologically "benign" meningioma is a rare, but well-documented event.
  • However, there are only four reported cases in the literature of metastatic spread from a purely intraventricular meningioma.
  • In this report, the authors present a rare case of the concurrent presentation of a histologically benign intraventricular meningioma and a solitary lung lesion which proved to be metastatic meningioma.
  • [MeSH-major] Cerebral Ventricle Neoplasms / pathology. Lung Neoplasms / secondary. Magnetic Resonance Imaging. Meningeal Neoplasms / pathology. Meningioma / secondary. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18282656.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Mucin-1; 0 / Receptors, Progesterone
  • [Number-of-references] 32
  •  go-up   go-down


20. Milker-Zabel S, Zabel-du Bois A, Ranai G, Trinh T, Unterberg A, Debus J, Lipson KE, Abdollahi A, Huber PE: SU11657 enhances radiosensitivity of human meningioma cells. Int J Radiat Oncol Biol Phys; 2008 Mar 15;70(4):1213-8
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SU11657 enhances radiosensitivity of human meningioma cells.
  • PURPOSE: To analyze the effect of the multireceptor tyrosine kinase inhibitor SU11657 (primarily vascular endothelial growth factor, platelet-derived growth factor) in combination with irradiation in freshly isolated primary human meningioma cells.
  • METHODS AND MATERIALS: Tumor specimens were obtained from meningioma patients undergoing surgery at the Department of Neurosurgery, University of Heidelberg, Germany.
  • Benign and atypical meningioma cells and human umbilical vein endothelial cells (HUVEC) were treated with SU11657 alone and in combination with 6-MV photons (0-10 Gy).
  • RESULTS: Radiation and SU11657 alone reduced cell proliferation in atypical and benign meningioma cells as well as in HUVEC in a dose-dependent manner.
  • SU11657 alone also reduced clonogenic survival of benign and atypical meningioma cells.
  • SU11657 increased radiosensitivity of human meningioma cells in clonogenic survival and cell number/proliferation assays.
  • The anticlonogenic and antiproliferative effects alone and the radiosensitization effects of SU11657 were more pronounced in atypical meningioma cells compared with benign meningioma cells.
  • CONCLUSION: Small-molecule tyrosine kinase inhibitors like SU11657 are capable of amplifying the growth inhibitory effects of irradiation in meningioma cells.
  • These data provide a rationale for further clinical evaluation of this combination concept, especially in atypical and malignant meningioma patients.
  • [MeSH-major] Meningeal Neoplasms / radiotherapy. Meningioma / radiotherapy. Organic Chemicals / pharmacology. Radiation Tolerance / drug effects. Receptor Protein-Tyrosine Kinases / antagonists & inhibitors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18234428.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Organic Chemicals; 0 / SU 11657; 0 / Vascular Endothelial Growth Factors; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  •  go-up   go-down


21. Falzon G, Pearson S, Murison R, Hall C, Siu K, Round A, Schültke E, Kaye AH, Lewis R: Myelin structure is a key difference in the x-ray scattering signature between meningioma, schwannoma and glioblastoma multiforme. Phys Med Biol; 2007 Nov 7;52(21):6543-53
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myelin structure is a key difference in the x-ray scattering signature between meningioma, schwannoma and glioblastoma multiforme.
  • Small angle x-ray scattering (SAXS) patterns of benign and malignant brain tumour tissue were examined.
  • This has clearly demonstrated that significant differences in the structure of myelin exist in the highly malignant glioblastoma multiforme as opposed to the benign: meningioma and schwannoma.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / radiography. Glioblastoma / diagnosis. Glioblastoma / radiography. Meningioma / diagnosis. Meningioma / radiography. Myelin Sheath / chemistry. Neurilemmoma / diagnosis. Neurilemmoma / radiography

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Schwannoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17951861.001).
  • [ISSN] 0031-9155
  • [Journal-full-title] Physics in medicine and biology
  • [ISO-abbreviation] Phys Med Biol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


22. Norden AD, Raizer JJ, Lamborn KR, Abrey LE, Chang SM, Gilbert MR, Cloughesy TF, Prados MD, Lieberman F, Wen P: Phase II trials of erlotinib or gefitinib in patients with recurrent meningiomas. J Clin Oncol; 2009 May 20;27(15_suppl):2062

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trials of erlotinib or gefitinib in patients with recurrent meningiomas.
  • : 2062 Background: No effective treatment is available for recurrent meningiomas when surgical and radiation options are exhausted.
  • The epidermal growth factor receptor (EGFR) is often over-expressed in meningiomas and may promote tumor growth.
  • In open label, single arm phase II studies of the EGFR inhibitors gefitinib (NABTC 00-01) and erlotinib (NABTC 01-03) for recurrent malignant gliomas, we included exploratory subsets of recurrent meningioma patients.
  • METHODS: Patients with recurrent histologically confirmed meningiomas and no more than two previous chemotherapy regimens were treated with gefitinib 500 mg/day or erlotinib 150 mg/day until tumor progression or unacceptable toxicity.
  • Eight patients (32%) had benign tumors, 9 (36%) atypical, and eight (32%) malignant.
  • For benign tumors, the 6-month progression-free survival (PFS6) was 29%, 12-month PFS (PFS12) 0%, 6-month overall survival (OS6) 63%, and 12-month OS (OS12) 50%.
  • CONCLUSIONS: Neither gefitinib nor erlotinib appear to have significant activity against recurrent meningioma.
  • The role of EGFR inhibitors in meningiomas is unclear but evaluation of EGFR inhibitors in combination with other targeted molecular agents may be warranted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964693.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Shirai W, Tokumitsu N, Sako K, Takahashi T: [Hemangiopericytoma at the transverse sinus presenting with intracerebral hemorrhage: case report]. No Shinkei Geka; 2005 Sep;33(9):895-900
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Based on the findings shown in this case report, hemangiopericytoma should be included in the differential diagnosis from benign meningioma.

  • Genetic Alliance. consumer health - Hemangiopericytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16164186.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


24. Shuto T, Inomori S, Fujino H, Nagano H, Hasegawa N, Kakuta Y: Cyst formation following gamma knife surgery for intracranial meningioma. J Neurosurg; 2005 Jan;102(s_supplement):134-139

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyst formation following gamma knife surgery for intracranial meningioma.
  • OBJECT: The authors conducted a study to evaluate the clinical significance of cyst formation or enlargement after gamma knife surgery (GKS) for intracranial benign meningiomas.
  • METHODS: The medical records of 160 patients with 184 tumors were examined for those with follow-up data of more than 2 years among 270 patients who underwent GKS for intracranial meningiomas between February 1992 and November 2001.
  • CONCLUSIONS: New cyst formation following GKS for benign intracranial meningioma is relatively rare; however, both preexisting and newly developed cysts tend to enlarge after GKS and often require surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28306456.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; cyst / gamma knife surgery / meningioma
  •  go-up   go-down


25. Monleón D, Morales JM, Gonzalez-Darder J, Talamantes F, Cortés O, Gil-Benso R, López-Ginés C, Cerdá-Nicolás M, Celda B: Benign and atypical meningioma metabolic signatures by high-resolution magic-angle spinning molecular profiling. J Proteome Res; 2008 Jul;7(7):2882-8
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign and atypical meningioma metabolic signatures by high-resolution magic-angle spinning molecular profiling.
  • Meningiomas are neoplasms that arise from the leptomeningeal covering of the brain and spinal cord, accounting for 15%-20% of CNS tumors.
  • The WHO classifies meningiomas into three histological grades: benign, atypical, and anaplasic in accordance with the clinical prognosis.
  • Atypical and anaplasic meningiomas tend to recur.
  • Sometimes, meningiomas with histological diagnosis of benign meningioma show clinical characteristics of atypical meningioma.
  • In this work, we show differences between benign and atypical meningiomas in HR-MAS molecular profiles of meningioma biopsies.
  • Metabolic differences between meningioma grades include changes in the levels of glutathione.
  • Glutamine and glutamate, which are related to glutathione metabolism and have been associated with tumor recurrence, are also increased in atypical meningiomas.
  • Other metabolites associated with tumor malignancy that show statistically significant differences between benign and atypical meningiomas include phosphocholine and phosphoethanolamine.
  • Overall, this work suggests that the additional information obtained by NMR metabolomics applied to biopsies of human meningiomas may be useful for assessing tumor grade and determining optimum treatment strategies.
  • [MeSH-major] Meningeal Neoplasms / metabolism. Meningioma / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18507434.001).
  • [ISSN] 1535-3893
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


26. Norden AD, Drappatz J, Wen PY: Advances in meningioma therapy. Curr Neurol Neurosci Rep; 2009 May;9(3):231-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in meningioma therapy.
  • Meningiomas are the most common primary brain tumors in adults.
  • Most of them are benign (World Health Organization grade I), slow-growing lesions, but some are classified as atypical (WHO grade II) or malignant (WHO grade III).
  • Surgical resection is curative when complete removal of a benign meningioma is possible.
  • Incompletely resected tumors and high-grade lesions are frequently treated with fractionated radiotherapy or stereotactic radiosurgery.
  • High-grade meningiomas tend to recur following maximal treatment with surgery and radiation.
  • As the molecular pathogenesis of meningiomas is elucidated, targeted drug therapies may prove useful.
  • [MeSH-major] Meningeal Neoplasms / therapy. Meningioma / therapy

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19348712.001).
  • [ISSN] 1534-6293
  • [Journal-full-title] Current neurology and neuroscience reports
  • [ISO-abbreviation] Curr Neurol Neurosci Rep
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 81
  •  go-up   go-down


27. Tena-Suck M, Collado-Ortiz MA, Rembao-Bojórquez D, Gestista N, García-Marquez A: Coexistence between meningioma and tuberculosis: case report. J Neurooncol; 2010 Sep;99(2):289-94
Genetic Alliance. consumer health - Tuberculosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistence between meningioma and tuberculosis: case report.
  • Histology showed a benign meningioma with many multinuclear giant cells, granulomas, and central caseating necrosis.
  • The authors describe the unusual case of coexistence between an occipital meningioma and tuberculosis in the same area that resembled metastasis.
  • [MeSH-major] Meningeal Neoplasms / complications. Meningioma / complications. Tuberculosis, Meningeal / complications

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20195701.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Stein PJ: A case of cerebellopontine angle meningioma presenting with neck and upper extremity pain. J Manipulative Physiol Ther; 2009 Nov-Dec;32(9):776-80
MedlinePlus Health Information. consumer health - Pain.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of cerebellopontine angle meningioma presenting with neck and upper extremity pain.
  • OBJECTIVE: The purpose of this case report is to describe and discuss the clinical presentation, diagnosis, and management of a patient with a cerebellopontine angle meningioma.
  • INTERVENTION AND OUTCOME: Magnetic resonance imaging studies of the neck and brain revealed a posterior fossa tumor, which was eventually diagnosed as a benign meningioma.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Cerebellar Neoplasms / radiography. Cerebellopontine Angle / pathology. Cerebellopontine Angle / radiography. Meningioma / pathology. Meningioma / radiography. Neck / physiopathology. Pain / etiology. Pain / physiopathology. Upper Extremity / physiopathology

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20004806.001).
  • [ISSN] 1532-6586
  • [Journal-full-title] Journal of manipulative and physiological therapeutics
  • [ISO-abbreviation] J Manipulative Physiol Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Decock CE, Kataria S, Breusegem CM, Van Den Broecke CM, Claerhout IJ: Ectopic meningioma anterior to the lacrimal gland fossa. Ophthal Plast Reconstr Surg; 2009 Jan-Feb;25(1):57-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ectopic meningioma anterior to the lacrimal gland fossa.
  • Anatomopathologic investigation of the excised specimen with immunohistochemistry revealed a benign meningioma of a meningotheliomatous type, containing multiple bone elements.
  • An ectopic orbital meningioma is rare, and this is the first case of a unique lateral localization of this lesion.
  • [MeSH-major] Choristoma / radiography. Lacrimal Apparatus / radiography. Meningeal Neoplasms. Meningioma. Orbital Neoplasms / radiography

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19273931.001).
  • [ISSN] 1537-2677
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucin-1; 0 / Vimentin
  •  go-up   go-down


30. Woo KS, Sung KS, Kim KU, Shaffer LG, Han JY: Characterization of complex chromosome aberrations in a recurrent meningioma combining standard cytogenetic and array comparative genomic hybridization techniques. Cancer Genet Cytogenet; 2008 Jan 1;180(1):56-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of complex chromosome aberrations in a recurrent meningioma combining standard cytogenetic and array comparative genomic hybridization techniques.
  • Meningiomas were among the first solid tumors recognized as having cytogenetic alterations.
  • The most consistent changes reported in grade I meningiomas were monosomy 22 or partial 22q deletion.
  • The vast majority of meningiomas are histologically benign, but the prognosis is determined by risk of recurrence after surgical treatment.
  • In the present study, a recurrent transitional meningioma deriving from the anterior portion of the falx cerebri was characterized by combining conventional cytogenetics and array comparative genomic hybridization (CGH).
  • The presence of a complex cytogenetic profile and progression-associated chromosomal abnormalities in a benign meningioma suggests the existence of underlying molecular events.

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18068535.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


31. Lee GC, Choi SW, Kim SH, Kwon HJ: Multiple extracranial metastases of atypical meningiomas. J Korean Neurosurg Soc; 2009 Feb;45(2):107-11

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple extracranial metastases of atypical meningiomas.
  • Meningiomas are usually benign neoplasms in which extracranial metastases occur very rarely.
  • We report a case of multiple extracranial metastases of an atypical meningioma following a local recurrence.
  • We performed a total mass removal, and the histopathologic findings were consistent with benign meningioma.
  • Eight months later, the meningioma recurred.
  • The histopathologic findings showed atypical meningioma.
  • The histopathologic findings of the spinal tumors showed atypical meningioma.
  • The results from perirenal biopsies were consistent with metastatic meningioma.
  • In conclusion, extracranial metastasis as well as local recurrence must be considered in atypical or anaplastic meningioma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Res Pract. 2008;204(5):305-14 [18374497.001]
  • [Cites] Spine (Phila Pa 1976). 2000 Mar 15;25(6):727-31 [10752106.001]
  • [Cites] J Neurosurg. 1964 Dec;21:1098-102 [14281384.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • [Cites] Neuropathol Appl Neurobiol. 1997 Dec;23(6):496-506 [9460716.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1455-65 [9414189.001]
  • [Cites] Oncology (Williston Park). 1996 May;10(5):747-56; discussion 756-9 [8738830.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(10):1172-7; discussion 1177-8 [8955436.001]
  • [Cites] J Neurosurg. 1989 Mar;70(3):478-82 [2915253.001]
  • [Cites] J Neurosurg. 1985 May;62(5):763-6 [3989597.001]
  • [Cites] AJNR Am J Neuroradiol. 1982 May-Jun;3(3):267-76 [6805276.001]
  • [Cites] Br J Cancer. 1978 Apr;37(4):644-7 [646935.001]
  • [Cites] Cancer. 1970 Oct;26(4):832-41 [5528265.001]
  • [Cites] Anticancer Drugs. 2003 Mar;14(3):247-50 [12634620.001]
  • [Cites] Brain Pathol. 2002 Apr;12(2):183-90 [11958372.001]
  • [Cites] Neurosurg Rev. 2006 Jan;29(1):36-40 [16220350.001]
  • (PMID = 19274122.001).
  • [ISSN] 2005-3711
  • [Journal-full-title] Journal of Korean Neurosurgical Society
  • [ISO-abbreviation] J Korean Neurosurg Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2651555
  • [Keywords] NOTNLM ; Anaplastic meningioma / Atypical meningioma / Extracranial metastasis
  •  go-up   go-down


32. Bodi I, Hortobágyi T, Buk S: A 72-year-old woman with right frontal extra-axial mass. Brain Pathol; 2008 Apr;18(2):279-82
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present a case of plasma cell predominant lymphoplasmacyte-rich meningioma with numerous crystalline inclusions.
  • Histology showed a benign meningioma with multifocal accumulation of numerous large cells with abundant eosinophilic cytoplasm, filled with lamellar inclusions and bipyramidal crystals.
  • Although plasma cell predominant lymphoplasmacyte-rich meningioma is not uncommon, to our knowledge, similar crystalline inclusions in plasma cells have not been reported previously in meningioma.
  • [MeSH-major] Brain Neoplasms / pathology. Frontal Lobe / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18363938.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Switzerland
  •  go-up   go-down


33. Das A, Tan WL, Smith DR: p53 point mutation is rare in meningiomas from Singaporean patients. Asian J Surg; 2005 Jan;28(1):7-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 point mutation is rare in meningiomas from Singaporean patients.
  • In Asian populations, meningiomas account for up to 35% of all central nervous system tumours, a significantly higher incidence than in Caucasian populations.
  • While several studies have examined p53 both at the level of the gene and the protein in both benign and malignant meningiomas, its role remains controversial, particularly with regard to the discrepancy between p53 over-expression and gene mutation.
  • We examined 19 benign meningiomas, all of which were known to over-express p53, and eight malignant meningiomas, of which three were known to over-express p53, for mutations in the p53 gene using polymerase chain reaction amplification and direct sequencing of exons 4 to 9, inclusive.
  • Only one single mutation was detected in a benign meningioma, confirming that p53 over-expression in meningiomas is commonly found in the absence of gene mutations, and that despite the significantly higher incidence of meningiomas in some Asian populations, this is not associated with a significantly higher rate of p53 mutations.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15691789.001).
  • [ISSN] 1015-9584
  • [Journal-full-title] Asian journal of surgery
  • [ISO-abbreviation] Asian J Surg
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


34. Kelsey CR, Marks LB: Somnolence syndrome after focal radiation therapy to the pineal region: case report and review of the literature. J Neurooncol; 2006 Jun;78(2):153-6
MedlinePlus Health Information. consumer health - Sleep Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors report a 29 year-old female who developed symptoms compatible with the somnolence syndrome after completing radiation therapy for a benign meningioma near the pineal region.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Cranial Irradiation / adverse effects. Meningioma / radiotherapy. Pineal Gland / radiation effects. Sleep Wake Disorders / etiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16575537.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 16
  •  go-up   go-down


35. Hu H, Yao HT, Zhang WP, Zhang L, Ding W, Zhang SH, Chen Z, Wei EQ: Increased expression of aquaporin-4 in human traumatic brain injury and brain tumors. J Zhejiang Univ Sci B; 2005 Jan;6(1):33-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Nineteen human brain specimens were obtained from the patients with traumatic brain injury, brain tumors, benign meningioma or early stage hemorrhagic stroke.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2000 Feb;6(2):159-63 [10655103.001]
  • [Cites] Brain Res Mol Brain Res. 2000 May 31;78(1-2):131-7 [10891592.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2002 Feb;72(2):262-5 [11796780.001]
  • [Cites] Brain Res Brain Res Rev. 2002 Jun;39(1):55-73 [12086708.001]
  • [Cites] J Anat. 2002 Jun;200(6):617-27 [12162729.001]
  • [Cites] J Neurosurg. 2003 Mar;98(3):565-9 [12650429.001]
  • [Cites] Acta Neuropathol. 2003 Aug;106(2):121-4 [12715185.001]
  • [Cites] J Biol Chem. 1988 Oct 25;263(30):15634-42 [3049610.001]
  • [Cites] J Neurosci. 1997 Jan 1;17(1):171-80 [8987746.001]
  • [Cites] J Biol Chem. 1997 Jun 27;272(26):16140-6 [9195910.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11981-6 [9751776.001]
  • (PMID = 15593389.001).
  • [ISSN] 1673-1581
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / AQP4 protein, human; 0 / Aquaporin 4; 0 / Aquaporins; 0 / Biomarkers
  • [Other-IDs] NLM/ PMC1390756
  •  go-up   go-down


41. Delgado-López PD, Martín-Velasco V, Castilla-Díez JM, Fernández-Arconada O, Corrales-García EM, Galacho-Harnero A, Rodríguez-Salazar A, Pérez-Mies B: Metastatic meningioma to the eleventh dorsal vertebral body: total en bloc spondylectomy. Case report and review of the literature. Neurocirugia (Astur); 2006 Jun;17(3):240-9
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic meningioma to the eleventh dorsal vertebral body: total en bloc spondylectomy. Case report and review of the literature.
  • INTRODUCTION: One in every thousand intracranial meningiomas metastatize extracranially.
  • To our knowledge, this is the first description of a total en bloc spondylectomy through a posterior approach for the treatment of an intraosseous metastatic meningioma to the eleventh dorsal vertebra.
  • CASE REPORT: In March 1996, a 37 year-old male underwent surgical resection for a left occipital intraventricular benign meningioma (WHO I).
  • Advice from a second pathologist was seeked, who suggested the diagnosis of intraosseous meningioma.
  • Definite pathology: benign meningioma (WHO I).
  • DISCUSSION: Distant metastases from intracranial meningiomas are rare entities, arising from benign lesions in, at least, 60% of cases.
  • Enam et al proposed a specific pathological score to differentiate benign, atypic and malignant meningiomas.
  • Such score correlates with the chance of metastatizing: more than 40% in malignant meningiomas compared to 3.8% of brain tumors overall.
  • [MeSH-major] Meningioma / pathology. Orthopedic Procedures / methods. Spinal Neoplasms / secondary. Spinal Neoplasms / surgery. Thoracic Vertebrae

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16855782.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


42. Gerber MA, Bahr SM, Gutmann DH: Protein 4.1B/differentially expressed in adenocarcinoma of the lung-1 functions as a growth suppressor in meningioma cells by activating Rac1-dependent c-Jun-NH(2)-kinase signaling. Cancer Res; 2006 May 15;66(10):5295-303
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein 4.1B/differentially expressed in adenocarcinoma of the lung-1 functions as a growth suppressor in meningioma cells by activating Rac1-dependent c-Jun-NH(2)-kinase signaling.
  • Meningiomas are the second most common brain tumor in adults, yet comparatively little is presently known about the dysregulated growth control pathways involved in their formation and progression.
  • One of the most frequently observed genetic changes in benign meningioma involves loss of protein 4.1B expression.
  • Previous studies from our laboratory have shown that protein 4.1B growth suppression in meningioma is associated with the activation of the c-Jun-NH(2)-kinase (JNK) pathway and requires localization of a small unique region (U2 domain) of protein 4.1B to the plasma membrane.
  • In this report, we show that protein 4.1B/differentially expressed in adenocarcinoma of the lung-1 (DAL-1) expression in meningioma cells in vitro results in JNK activation, which requires the sequential activation of Src, Rac1, and JNK.
  • Last, protein 4.1B/DAL-1 regulation of this critical growth control pathway in meningioma cells requires the presence of the U2 domain.
  • Collectively, these observations provide the first mechanistic insights into the function of protein 4.1B as a growth regulator in meningioma cells.
  • [MeSH-major] JNK Mitogen-Activated Protein Kinases / metabolism. Membrane Proteins / metabolism. Meningioma / enzymology. Meningioma / pathology. Tumor Suppressor Proteins / metabolism. rac1 GTP-Binding Protein / metabolism

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16707455.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin A; 0 / EPB41L3 protein, human; 0 / Membrane Proteins; 0 / Microfilament Proteins; 0 / RAC1 protein, human; 0 / Retinoblastoma Protein; 0 / Tumor Suppressor Proteins; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; EC 2.7.11.25 / MAP Kinase Kinase Kinases; EC 2.7.11.25 / mitogen-activated protein kinase kinase kinase 11; EC 3.6.5.2 / rac1 GTP-Binding Protein
  •  go-up   go-down


43. Qi ZG, Li YX, Wang Y, Geng DY, Li KC, Shen TZ, Chen XR: Lipid signal in evaluation of intracranial meningiomas. Chin Med J (Engl); 2008 Dec 5;121(23):2415-9
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lipid signal in evaluation of intracranial meningiomas.
  • BACKGROUND: Using magnetic resonance imaging, diagnosis of malignant meningioma from benign meningioma with atypical features is uncertain.
  • We evaluated the value of lipid signal in differentiating intracranial meningiomas.
  • RESULTS: Twenty-nine meningiomas were histologically benign (eleven meningothelial, thirteen fibrous, four transitional and one microcystic), three were atypical, and two were anaplastic.
  • Lipid signal was detected in ten cases: two anaplastic, three atypical, two fibrous and three meningothelial meningiomas.
  • With creatinine peak in the normal white matter chosen as internal standard, lipid/creatinine ratios of anaplastic, atypical and benign meningiomas were 0.844 +/- 0.027 (range from 0.725 to 0.994), 0.465 +/- 0.023 (range from 0.239 to 0.724), and 0.373 +/- 0.016 (range from 0.172 to 0.571) respectively.
  • Patchy necrosis was observed in anaplastic meningioma, while focal necrosis was noted in atypical meningioma with HE stain.
  • However, no necrosis was found in benign group.
  • KP-1 stain demonstrated histocytes containing lipids in the necrotic region of anaplastic and atypical meningioma.
  • CONCLUSION: The lipid signal at 1.3 ppm is a useful marker in evaluating the malignancy of intracranial meningiomas, especially in the differential diagnosis of anaplastic meningioma.
  • [MeSH-major] Magnetic Resonance Imaging / methods. Magnetic Resonance Spectroscopy / methods. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19102960.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


44. Moon HS, Jung S, Jung TY, Cao VT, Moon KS, Kim IY: Possible role of matrix metalloproteinase in osteolytic intracranial meningiomas. J Korean Neurosurg Soc; 2010 Jan;47(1):11-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Possible role of matrix metalloproteinase in osteolytic intracranial meningiomas.
  • OBJECTIVE: Abnormalities of the bone are frequently encountered in patients with meningioma, and hyperostosis and endostosis are common bone alterations in these tumors.
  • Extensive bony destruction is very unusual in patients with meningioma.
  • We report six cases of intracranial meningioma associated with an osteolytic lesion of the skull and discuss the underlying mechanisms that may be responsible for bone destruction in patients with meningioma.
  • We investigated the potential role of matrix metalloproteinase (MMP) in meningioma-associated osteolysis.
  • Histological examination revealed benign meningioma in four cases, and two cases of atypical meningioma.
  • Patients did not have a poor prognosis except one case of recurred atypical meningioma.
  • CONCLUSION: Osteolysis of the skull in patients with meningiomas might not be indicative of malignant pathological features and poor prognosis.
  • Invasion to the extracranial portion and osteolysis might be associated with MMP-2 expression in meningioma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1992 Jun;30(6):932-5 [1614599.001]
  • [Cites] J Korean Neurosurg Soc. 2008 Jan;43(1):34-6 [19096543.001]
  • [Cites] Clin Radiol. 1997 Jul;52(7):546-9 [9240709.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(5):481-6 [10392203.001]
  • [Cites] J Korean Med Sci. 2000 Jun;15(3):309-14 [10895974.001]
  • [Cites] J Neurosurg. 2001 Nov;95(5):839-44 [11702875.001]
  • [Cites] Clin Cancer Res. 2002 Jun;8(6):1932-9 [12060638.001]
  • [Cites] Int J Mol Med. 2003 Dec;12(6):977-81 [14612977.001]
  • [Cites] Nat Med. 2006 Aug;12(8):895-904 [16892035.001]
  • [Cites] Radiology. 1977 May;123(2):375-7 [847205.001]
  • [Cites] Mil Med. 1972 May;137(5):196-8 [4623534.001]
  • [Cites] J Pathol. 1970 May;101(1):57-8 [5458408.001]
  • [Cites] Can J Neurol Sci. 1997 Feb;24(1):3-15 [9043741.001]
  • [Cites] Anticancer Res. 1997 Nov-Dec;17(6B):4151-62 [9428349.001]
  • [Cites] No Shinkei Geka. 1997 Dec;25(12):1097-100 [9430144.001]
  • [Cites] Clin Exp Metastasis. 1999;17(7):555-66 [10845554.001]
  • [Cites] Cell Mol Life Sci. 2000 Jan 20;57(1):5-15 [10949577.001]
  • [Cites] Cancer. 2002 Feb 1;94(3):765-72 [11857311.001]
  • [Cites] Science. 2002 Mar 29;295(5564):2387-92 [11923519.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):537-49 [12842083.001]
  • [Cites] Neuropathology. 2003 Dec;23(4):275-81 [14719542.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):29-37 [15015767.001]
  • [Cites] J Neurosurg. 1994 Jul;81(1):69-77 [8207529.001]
  • (PMID = 20157372.001).
  • [ISSN] 1598-7876
  • [Journal-full-title] Journal of Korean Neurosurgical Society
  • [ISO-abbreviation] J Korean Neurosurg Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2817509
  • [Keywords] NOTNLM ; Matrix metalloproteinase / Meningioma / Osteolytic
  •  go-up   go-down


45. Ali S, Nassar A, Siddiqui MT: Crush preparations of meningiomas: can grading be accomplished? Diagn Cytopathol; 2008 Nov;36(11):827-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Crush preparations of meningiomas: can grading be accomplished?
  • Crush preparations (CP) for the diagnosis of meningioma are routinely performed in the frozen section suite when tissue is submitted for intraoperative consultation.
  • The goal of this study was to examine the cytologic features of meningiomas in CP and evaluate if benign meningioma (Grade 1), atypical meningioma (Grade 2), and malignant meningioma (Grade 3) can be diagnosed on CP.
  • All cases of meningioma (1999-2007), which were submitted for frozen section at our institution, were retrospectively reviewed.
  • A total of 107 meningiomas cases were reviewed.
  • Using the final histopathologic diagnosis as the gold standard, there were 72 (Grade 1), 22 (Grade 2), and 13 (Grade 3) meningioma cases, which were studied.
  • In conclusion, this study reviews the salient cytologic features of Grades 1-3 meningiomas.
  • It demonstrates that it is difficult to separate Grade 1 from Grade-2 meningioma on CP, and last, Grade-3 meningioma can be easily diagnosed on CP.
  • [MeSH-major] Cytological Techniques / methods. Meningeal Neoplasms / pathology. Meningioma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18831022.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Widdel L, Kleinschmidt-DeMasters BK, Kindt G: Tumor-to-tumor metastasis from hematopoietic neoplasms to meningiomas: report of two patients with significant cerebral edema. World Neurosurg; 2010 Jul;74(1):165-71
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-to-tumor metastasis from hematopoietic neoplasms to meningiomas: report of two patients with significant cerebral edema.
  • OBJECTIVE: To report two examples of benign meningiomas in which metastatic tumor deposits from the patient's hematopoietic neoplasm to the meningioma caused significant peritumoral edema, necessitating semiemergent surgical resection.
  • Clinical suspicion in both patients was an atypical or anaplastic meningioma due to the edema.
  • RESULTS: One patient had multiple myeloma associated with extensive necrosis within his otherwise benign convexity meningioma; first diagnosis of his IgG, kappa-restricted plasma cell dyscrasia was made from this tumor-to-tumor meningioma specimen.
  • Dural marginal zone lymphoma was identified within epidural, intradural, and subdural spaces, in the same location as an underlying benign meningioma.
  • CONCLUSIONS: Although rare, neurosurgeons should be aware of the entity of tumor-to-tumor metastasis as, in large series, meningiomas are the third most frequent recipient tumor type and pituitary adenomas, the fifth most frequent, probably reflecting their rich vascularity.
  • [MeSH-major] Brain Edema / etiology. Image Processing, Computer-Assisted. Lymphoma, B-Cell, Marginal Zone / diagnosis. Magnetic Resonance Imaging. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / secondary. Meningioma / diagnosis. Multiple Myeloma / diagnosis. Multiple Myeloma / secondary. Neoplasms, Second Primary / diagnosis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21300009.001).
  • [ISSN] 1878-8769
  • [Journal-full-title] World neurosurgery
  • [ISO-abbreviation] World Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Mattei TA, Mattei JA, Ramina R, Aguiar PH, Plese JP, Marino Jr R: Edema and malignancy in meningiomas. Clinics (Sao Paulo); 2005 Jun;60(3):201-6
Genetic Alliance. consumer health - Edema.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Edema and malignancy in meningiomas.
  • PURPOSE: In recent years there have been many attempts to define a subset of aggressive malignant meningiomas based on histopathology and imaging technologies.
  • The purpose of this study was to evaluate the level of peritumoral edema and its volume using the imaging technologies, computer tomography and magnetic resonance imaging, and correlate these results with the histological WHO classification.
  • METHODS: The cases of 55 patients with meningiomas who underwent surgery at the Hospital das Clinicas (Fac Med Univ Sao Paulo) between September 1993 and September 1997 were reviewed.
  • The level of edema according to the classification of Ide et al. (1995) was compared to the histological WHO classification.
  • Histological classification was: benign meningioma--43 cases; atypical meningiomas--11 cases; malignant meningioma--1 case.
  • CONCLUSIONS: These results suggest that the degree of edema as revealed by computer tomography and magnetic resonance imaging can be an important clinical predictive factor for the histological grade of the meningioma.
  • [MeSH-major] Brain Edema / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15962080.001).
  • [ISSN] 1807-5932
  • [Journal-full-title] Clinics (São Paulo, Brazil)
  • [ISO-abbreviation] Clinics (Sao Paulo)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


48. Fèvre-Montange M, Champier J, Durand A, Wierinckx A, Honnorat J, Guyotat J, Jouvet A: Microarray gene expression profiling in meningiomas: differential expression according to grade or histopathological subtype. Int J Oncol; 2009 Dec;35(6):1395-407
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microarray gene expression profiling in meningiomas: differential expression according to grade or histopathological subtype.
  • Meningiomas, one of the largest subgroup of intracranial tumours are generally benign, but can progress to malignancy.
  • They are classified into the three World Health Organization grades: benign, atypical and anaplastic meningiomas.
  • We have performed a microarray transcriptomic study on 17 meningiomas of different malignancy using CodeLink Uniset Human Whole Genome Bioarrays to try to distinguish the different grades and histopathological subtypes.
  • Unsupervised hierarchical clustering classified the meningiomas into groups A, B and C, which corresponded to the three grades except for 3 benign meningiomas with higher proliferation indexes and/or recurrence, included in the atypical group.
  • In the benign tumours, we identified genes with signatures specific for fibroblastic meningiomas (FBLN1, Tenascin C and MMP2 encoding extracellular matrix proteins) and for meningothelial meningiomas (MLPH, DEFB1 and FAT3), suggesting different mechanisms involved in the tumorigenesis of these subtypes.
  • This microarray-based expression profiling study revealed candidate genes and pathways that may contribute to a better understanding of the recurrence of a benign meningioma.
  • Our results might make it possible to determine which benign meningiomas might recur despite complete resection, and will provide helpful information for neurosurgeons in the follow-up of the patients.
  • [MeSH-major] Gene Expression Profiling. Meningeal Neoplasms / genetics. Meningeal Neoplasms / pathology. Meningioma / genetics. Meningioma / pathology


49. De Moura J, Kavalec FL, Doghman M, Rosati R, Custodio G, Lalli E, Cavallari GM, Santa Maria J, Figueiredo BC: Heterozygous TP53stop146/R72P fibroblasts from a Li-Fraumeni syndrome patient with impaired response to DNA damage. Int J Oncol; 2010 Apr;36(4):983-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In order to investigate the disruption of the p53 function in a patient presenting this mutation and the TP53Arg72Pro polymorphism who had so far suffered five malignant tumors and a benign meningioma, we tested her fibroblasts in response to DNA damage by evaluating the proliferation rate, apoptosis, and disruption of the TP53 pathway.
  • The proband's heterozygous fibroblasts were not as efficient as control fibroblasts or those of her mother, who carried only the TP53Arg72Pro polymorphism, in causing cell arrest and cell death after DNA damage, which was correlated with diminished TP21 protein levels.

  • Genetic Alliance. consumer health - Li Fraumeni syndrome.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20198344.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / CDKN1A protein, human; 0 / Codon, Nonsense; 0 / Codon, Terminator; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 6PLQ3CP4P3 / Etoposide
  •  go-up   go-down


50. Askoxylakis V, Zabel-du Bois A, Schlegel W, Debus J, Huber P, Milker-Zabel S: Patterns of failure after stereotactic radiotherapy of intracranial meningioma. J Neurooncol; 2010 Jul;98(3):367-72
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of failure after stereotactic radiotherapy of intracranial meningioma.
  • The aim of this work is to evaluate patterns of failure in patients with recurrent meningioma after stereotactic radiotherapy.
  • Of 411 patients with intracranial meningioma treated with radiotherapy at our institution, 22 patients with local tumor progression diagnosed by magnetic resonance imaging (MRI) after radiotherapy (RT) were identified and further investigated.
  • The histologic grade of the meningiomas was World Health Organization (WHO) grade I in 54.5%, WHO grade II in 27.3%, and WHO grade III in 9.1% of cases.
  • Median recurrence-free survival was 46 months for patients with benign meningioma (WHO grade I) and 31.5 months for patients with higher-grade meningioma (WHO grade II/III).
  • In the WHO grade I group, three recurrences were central and nine were marginal, whereas in the WHO grade II/III group seven recurrences were central and one was marginal.
  • Median time to local tumor progression and site of local recurrence significantly depended on histological grade of meningioma.
  • Regarding site of failure, improvement of dose coverage for benign meningiomas and dose escalation for high-grade tumors might further improve therapy outcome.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Radiosurgery / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20012910.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Chahlavi A, Staugaitis SM, Yahya R, Vogelbaum MA: Intracranial collision tumor mimicking an octreotide-SPECT positive and FDG-PET negative meningioma. J Clin Neurosci; 2005 Aug;12(6):720-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial collision tumor mimicking an octreotide-SPECT positive and FDG-PET negative meningioma.
  • We report an unusual case of a "collision tumor" consisting of a renal cell carcinoma metastasis to an intracranial meningioma.
  • MRI characteristics of the tumor were consistent with meningioma.
  • On octreotide-SPECT and F-18 fluorodeoxyglucose (FDG)-PET scans, the lesion showed octreotide uptake but did not accumulate FDG, both of which are consistent with a diagnosis of benign meningioma.
  • Microscopic examination was consistent with renal cell carcinoma with a minor portion consisting of meningioma.
  • CONCLUSION: Collision tumor involving metastatic renal cell carcinoma to an intracranial meningioma is a rare occurrence.
  • A high degree of suspicion of intracranial metastasis should be maintained for patients who have known systemic cancer and are found incidentally to have a dural-based mass lesion.
  • [MeSH-major] Brain Neoplasms / secondary. Carcinoma / pathology. Kidney Neoplasms / pathology. Meningioma / secondary. Tomography, Emission-Computed, Single-Photon

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16115558.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


52. Goh KY, Poon WS, Chan DT, Ip CP: Tissue plasminogen activator expression in meningiomas and glioblastomas. Clin Neurol Neurosurg; 2005 Jun;107(4):296-300
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue plasminogen activator expression in meningiomas and glioblastomas.
  • OBJECTIVES: Enzyme-linked immunosorbent assay (ELISA) and Western blotting techniques were used to investigate and compare the expression of tissue plasminogen activator (tPA) in benign (meningioma) and malignant (glioblastoma) human brain tumours.
  • METHODS: A total of 22 tumour samples comprising 11 meningiomas and 11 glioblastomas with adjacent peritumoural tissue were analysed.
  • RESULTS: The mean tPA content of meningiomas was approximately half that of glioblastomas (55.40 (S.D.
  • Comparing tPA quantity in tumour and peritumoural tissue, there was a significant difference for meningiomas (55.40 (S.D.
  • Comparing tumour with normal brain tissue, there was no difference for meningiomas (55.40 (S.D.
  • Western blotting showed that in the meningioma group, the molecular weight pattern was constant with a dominant well-defined band at 41kD.
  • CONCLUSION: These results indicate that (1) tPA is present in larger quantities in glioblastoma compared to meningioma and normal brain, (2) tPA quantity is not significantly different in the peritumoural tissue adjacent to glioblastoma but is significantly less for meningioma, and (3) tPA is expressed in more heterogenous forms in glioblastoma.
  • [MeSH-major] Brain Neoplasms / enzymology. Glioblastoma / enzymology. Meningeal Neoplasms / enzymology. Meningioma / enzymology. Tissue Plasminogen Activator / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15885387.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 3.4.21.68 / Tissue Plasminogen Activator
  •  go-up   go-down


53. Linskey ME, Davis SA, Ratanatharathorn V: Relative roles of microsurgery and stereotactic radiosurgery for the treatment of patients with cranial meningiomas: a single-surgeon 4-year integrated experience with both modalities. J Neurosurg; 2005 Jan;102(s_supplement):59-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relative roles of microsurgery and stereotactic radiosurgery for the treatment of patients with cranial meningiomas: a single-surgeon 4-year integrated experience with both modalities.
  • OBJECT: The authors sought to assess the respective roles of microsurgery and gamma knife surgery (GKS) in the treatment of patients with meningiomas.
  • METHODS: The authors culled from a 4-year prospective database data on 74 cases of meningiomas.
  • Simpson Grade 1 or 2 resection was achieved in 86.1% of patients who underwent microsurgery.
  • Patients who underwent GKS received a mean margin dose of 16.4 Gy (range 14-20 Gy).
  • In patients with benign meningiomas GKS tumor control was 96.8% with one recurrence at the margin.
  • The recurrence rate was zero of 27 for Simpson Grade 1 or 2 resection and three of four for higher grades in those patients who underwent microsurgery.
  • Symptoms improved in 48.4% of patients undergoing microsurgery and 16.7% of those who underwent GKS.
  • CONCLUSIONS: Both GKS and microsurgery serve important roles in the overall management of patients with meningiomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28306454.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; gamma knife surgery / meningioma / microsurgery / skull base surgery / stereotaxy
  •  go-up   go-down


54. Marosi C, Hassler M, Roessler K, Reni M, Sant M, Mazza E, Vecht C: Meningioma. Crit Rev Oncol Hematol; 2008 Aug;67(2):153-71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningioma.
  • Meningiomas are mostly benign tumours originating from the arachnoid cap cells, represent 13-26% of all intracranial tumours.
  • Five-year survival for typical meningiomas exceeds 80%, but is poorer (5-year survival <60%) in malignant and atypical meningiomas.
  • Radiotherapy is currently used in the clinical practice in atypical, malignant or recurrent meningioma at a total dose of 45-60Gy.
  • Radiosurgery has gained more and more importance in the management of meningiomas, especially in meningiomas that cannot be completely resected as for many skull base meningiomas.
  • [MeSH-major] Meningeal Neoplasms / therapy. Meningioma / therapy

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18342535.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 184
  •  go-up   go-down


55. Goldsmith B, McDermott MW: Meningioma. Neurosurg Clin N Am; 2006 Apr;17(2):111-20, vi
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningioma.
  • Total excision is an appropriate treatment option for patients with benign meningiomas that are resectable with minimal morbidity.
  • Fractionated conformal radiotherapy is an appropriate primary treatment option for patients with benign meningiomas of all sizes and all sites.
  • It is particularly appropriate and preferred for optic nerve sheath meningiomas, for which there are few alternatives.
  • [MeSH-major] Meningeal Neoplasms. Meningioma

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16793503.001).
  • [ISSN] 1042-3680
  • [Journal-full-title] Neurosurgery clinics of North America
  • [ISO-abbreviation] Neurosurg. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 56
  •  go-up   go-down


56. Llauger J, Aixut S, Cañete N, Palmer J, Solà M, Bagué S: Meningioma of the scapula. Skeletal Radiol; 2008 Feb;37(2):169-71
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningioma of the scapula.
  • Meningiomas account for approximately 15% of all intracranial tumors and are the most common non-glial primary tumors of the central nervous system.
  • Most meningiomas are benign neoplasms with characteristic imaging features.
  • Primary extradural meningiomas account for only 1-2% of all meningiomas.
  • They must be differentiated from intradural meningiomas with secondary extradural extension and/or metastases.
  • The vast majority of extradural meningiomas are found in the skull or in the head and neck region.
  • We report on an extremely rare case of primary extradural meningioma that was located in the scapula.
  • To the best of our knowledge, this form of presentation of an extradural meningioma has not been previously described.
  • [MeSH-major] Bone Neoplasms / diagnosis. Meningioma / diagnosis. Scapula / diagnostic imaging. Scapula / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 2005 Sep;26(8):2053-6 [16155159.001]
  • [Cites] J Neurosurg. 2000 Dec;93(6):940-50 [11117866.001]
  • [Cites] Jpn J Clin Oncol. 2000 Jul;30(7):313-7 [11007165.001]
  • [Cites] Am J Surg Pathol. 1996 Apr;20(4):492-9 [8604818.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Aug;18(7):1335-7 [9282866.001]
  • [Cites] Hum Pathol. 1991 May;22(5):469-74 [1709609.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):453-60 [9130993.001]
  • [Cites] Ann Thorac Surg. 2006 May;81(5):1903-4 [16631706.001]
  • [Cites] Skeletal Radiol. 2001 Nov;30(11):639-42 [11810156.001]
  • (PMID = 18030466.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


57. Nakasu S, Fukami T, Jito J, Nozaki K: Recurrence and regrowth of benign meningiomas. Brain Tumor Pathol; 2009;26(2):69-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence and regrowth of benign meningiomas.
  • The World Health Organization (WHO) grading system for meningioma is helpful for predicting aggressive subtypes.
  • However, even benign meningiomas sometimes show relatively rapid growth and may recur after total removal.
  • We attempted to find histopathological features that would be valuable for predicting recurrence or regrowth of WHO grade I meningiomas.
  • We investigated 135 benign meningiomas, of which 120 were totally removed (Simpson's grade I-III).
  • On the other hand, the histological features of sheet-like growth, prominent nucleoli, and necrosis did not correlate with recurrence, because they were relatively rare in grade I tumors.
  • MIB-1 index and Simpson's grade significantly correlated with retreatment in both univariate and multivariate analyses.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Recurrence, Local / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19856217.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


58. Amoli FA, Mehrabani PM, Tari AS: Aggressive orbital optic nerve meningioma with benign microscopic features: a case report. Orbit; 2007 Dec;26(4):271-4
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive orbital optic nerve meningioma with benign microscopic features: a case report.
  • Primary optic nerve meningiomas occur at lower ages than meningiomas arising from the coverings of the brain and spinal cord.
  • Here we report the case of a 20-year-old female with an aggressive orbital meningioma referred to the Ophthalmology Department of the Farabi Hospital in Tehran.
  • The patient had a history of orbital meningioma from 10 years ago and several surgical resections due to tumor recurrence during these 10 years.
  • Microscopic study showed meningotheliomatous meningioma with extensive involvement of the optic nerve and invasion of the optic disc, sclera and choroid.
  • The interesting aspect of this case was the aggressive behavior of the tumor with intraocular invasion, despite its benign histopathological features, which led to wide exenteration of the eye together with resection of the upper and lower lids.
  • [MeSH-major] Meningioma / pathology. Optic Nerve Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18097966.001).
  • [ISSN] 0167-6830
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


59. Kalamarides M, Peyre M, Giovannini M: Meningioma mouse models. J Neurooncol; 2010 Sep;99(3):325-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningioma mouse models.
  • Meningiomas, although mostly benign, may sometimes present aggressive features and raise issues concerning alternative treatment options besides surgery.
  • In order to gain new insights in meningioma biology and develop alternative treatments, several meningioma mouse models have been engineered during the past two decades.
  • As rodents very rarely develop spontaneous meningiomas, animal models have been first developed by implanting human meningioma cells derived from a primary tumor and meningioma cell lines subcutaneously into athymic mice.
  • Induction of de novo meningiomas in rodents with mutagens, such as nitrosourea, has also been reported.
  • Advances in our understanding of molecular genetics of meningioma have pinpointed the central role of NF2 tumor suppressor gene in the pathogenesis of those tumors.
  • These discoveries have led to the creation of a genetically engineered model utilizing conditional mutagenesis to specifically inactivate the mouse Nf2 gene in arachnoidal cells, resulting in the formation of intracranial meningothelial hyperplasia and meningiomas and thus reproducing the main mechanism of human meningeal tumorigenesis.
  • This powerful new technology significantly improves on prior models and may open avenues of investigation never before possible in meningioma research.
  • We present here a review of current meningioma mouse models used in translational therapeutics with associated imaging and pre-clinical studies.
  • [MeSH-major] Disease Models, Animal. Meningeal Neoplasms / pathology. Meningioma / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20734219.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


60. Wrobel G, Roerig P, Kokocinski F, Neben K, Hahn M, Reifenberger G, Lichter P: Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression. Int J Cancer; 2005 Mar 20;114(2):249-56
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression.
  • To identify gene expression profiles associated with human meningiomas of different World Health Organization (WHO) malignancy grades, we analyzed 30 tumors (13 benign meningiomas, WHO grade I; 12 atypical meningiomas, WHO grade II; 5 anaplastic meningiomas, WHO grade III) for the expression of 2,600 genes using cDNA-microarray technology.
  • Receiver operator curve (ROC) analysis with a cutoff value of 45% selection probability identified 37 genes with decreased and 27 genes with increased expression in atypical and anaplastic meningiomas, compared to benign meningiomas.
  • Supervised classification of the tumors did not reveal specific expression patterns representative of each WHO grade.
  • However, anaplastic meningiomas could be distinguished from benign meningiomas by differential expression of a distinct set of genes, including several ones associated with cell cycle regulation and proliferation.
  • Taken together, our microarray-based expression profiling revealed interesting novel candidate genes and pathways that may contribute to meningioma progression.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Meningeal Neoplasms / genetics. Meningioma / genetics. Oligonucleotide Array Sequence Analysis

  • Genetic Alliance. consumer health - Meningioma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15540215.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


61. Manzano-Palomo MS, Egido JA: [Pontine stroke secondary to a foramen magnum meningioma]. Rev Neurol; 2005 Jun 1-15;40(11):668-70
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pontine stroke secondary to a foramen magnum meningioma].
  • [Transliterated title] Ictus pontino secundario a meningioma de foramen magno.
  • INTRODUCTION: Meningioma is one of the most frequent tumours affecting the central nervous system, with an estimated incidence of between 15 and 20% of all brain tumours.
  • They are generally benign and slow growing.
  • CASE REPORT: A right-handed 75-year-old female patient with a personal history of arterial hypertension, who visited the Emergency Department because of the sudden onset of severe dysarthria, accompanied by loss of strength in the left limbs, supranuclear facial palsy on the left side and Horner syndrome on the right.
  • Magnetic resonance imaging of the head revealed a foramen magnum meningioma, with vertebrobasilar vascular distortion.
  • CONCLUSIONS: The case reported here is unique, since it describes a meningioma of the posterior fossa that appears in the form of the initial symptoms of a pontine stroke due to a vascular disorder.
  • [MeSH-major] Cerebral Infarction / etiology. Foramen Magnum. Meningeal Neoplasms / complications. Meningioma / complications. Pons / blood supply

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15948070.001).
  • [ISSN] 0210-0010
  • [Journal-full-title] Revista de neurologia
  • [ISO-abbreviation] Rev Neurol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


62. Alexiou GA, Vartholomatos G, Tsiouris S, Papadopoulos A, Kyritsis AP, Polyzoidis KS, Voulgaris S, Fotopoulos AD: Evaluation of meningioma aggressiveness by (99m)Tc-Tetrofosmin SPECT. Clin Neurol Neurosurg; 2008 Jul;110(7):645-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of meningioma aggressiveness by (99m)Tc-Tetrofosmin SPECT.
  • OBJECTIVES: Although meningiomas usually have a benign clinical course, atypical and malignant types of this brain tumor are associated with high recurrence rates and poor outcome; thus, DNA ploidy and S-phase -- as determined by DNA flow cytometry -- are useful indicators of their biological behavior.
  • This study evaluated whether (99m)Tc-Tetrofosmin ((99m)Tc-TF) uptake correlates with meningioma proliferative activity, as assessed by flow cytometry analysis.
  • PATIENTS AND METHODS: Ten consecutive patients (3 males, 7 females, mean age 64.6 years) with a diagnosis of a symptomatic intracranial meningioma, planned to undergo surgery, were studied.
  • RESULTS: Benign meningiomas were diagnosed in 8/10 cases, the remaining 2/10 patients had anaplastic lesions.
  • There was also a positive correlation between tracer uptake and the level of aneuploidy and tumor grade.
  • CONCLUSION: These results imply that (99m)Tc-TF brain SPECT may have the ability to discriminate benign meningiomas from malignant meningiomas pre-operatively, the tracer uptake being a likely indicator of their proliferative activity.
  • [MeSH-major] Meningeal Neoplasms / radionuclide imaging. Meningioma / radionuclide imaging. Organophosphorus Compounds. Organotechnetium Compounds. Tomography, Emission-Computed, Single-Photon / methods

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18471956.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Organophosphorus Compounds; 0 / Organotechnetium Compounds; 0 / technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane
  •  go-up   go-down


63. Nakasu S, Fukami T, Jito J, Matsuda M: Microscopic anatomy of the brain-meningioma interface. Brain Tumor Pathol; 2005;22(2):53-7
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microscopic anatomy of the brain-meningioma interface.
  • We analyzed the relation between meningioma and the brain in 50 surgical cases.
  • So-called capsule formation was seen in 20 meningiomas, of which 13 were categorized as thin and 7 as thick.
  • In 21 meningiomas the arachnoid membrane was intact, and 10 meningiomas had no underlying arachnoid membrane.
  • The degree of arachnoid disruption correlated with the tumor grade, perifocal edema, pial blood supply on angiography, and tumor size.
  • The existence of brain invasion correlated with the tumor grade and partially with tumor size.
  • Meningiomas were usually demarcated by a basement membrane that was collagen type 4 (Col4)-positive.
  • However, atypical and anaplastic meningiomas usually lacked Col4 staining at the interface.
  • In two benign meningiomas that looked like an invasive growth, Col4 staining was seen above the brain.
  • [MeSH-major] Brain / ultrastructure. Meningeal Neoplasms / ultrastructure. Meningioma / ultrastructure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095106.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Amyloid beta-Protein Precursor; 0 / Collagen Type IV; 0 / Glial Fibrillary Acidic Protein; 0 / Mucin-1; 0 / Neoplasm Proteins; 0 / Neurofilament Proteins; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


64. Pfister C, Ritz R, Pfrommer H, Bornemann A, Tatagiba MS, Roser F: Are there attacking points in the eicosanoid cascade for chemotherapeutic options in benign meningiomas? Neurosurg Focus; 2007;23(4):E8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are there attacking points in the eicosanoid cascade for chemotherapeutic options in benign meningiomas?
  • OBJECT: The current treatment for recurrent or malignant meningiomas with adjuvant therapies has not been satisfactory, and there is an intense interest in evaluating new molecular markers to act as therapeutic targets.
  • Enzymes of the arachidonic acid (AA) cascade such as cyclooxygenase (COX)-2 or 5-lipoxygenase (5-LO) are upregulated in a number of epithelial tumors, but to date there are hardly any data about the expression of these markers in meningiomas.
  • To find possible targets for chemotherapeutic intervention, the authors evaluated the expression of AA derivatives at different molecular levels in meningiomas.
  • METHODS: One hundred and twenty-four meningioma surgical specimens and normal human cortical tissue samples were immunohistochemically and cytochemically stained for COX-2, COX-1, 5-LO, and prostaglandin E receptor 4 (PTGER4).
  • RESULTS: Sixty (63%) of 95 benign meningiomas, 21 (88%) of 24 atypical meningiomas, all five malignant meningiomas, and all normal human cortex samples displayed high COX-2 immunoreactivity.
  • The PCR analysis demonstrated no changes in eicosanoid expression among meningiomas of different World Health Organization grades and in normal human cortical and dura mater tissue.
  • CONCLUSIONS: Eicosanoid derivatives COX-1, COX-2, 5-LO, and PTGER4 enzymes show a high universal expression in meningiomas but are not upregulated in normal human cortex and dura tissue.
  • This finding of the ubiquitous presence of these enzymes in meningiomas offers an excellent baseline for testing upcoming chemotherapeutic treatments.
  • [MeSH-major] Eicosanoids / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961045.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Eicosanoids; 0 / PTGER4 protein, human; 0 / RNA, Messenger; 0 / Receptors, Prostaglandin E; 0 / Receptors, Prostaglandin E, EP4 Subtype; EC 1.13.11.34 / Arachidonate 5-Lipoxygenase; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  •  go-up   go-down


65. Maes L, Kalala JP, Cornelissen M, De Ridder L: PCNA, Ki-67 and hTERT in residual benign meningiomas. In Vivo; 2006 Mar-Apr;20(2):271-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PCNA, Ki-67 and hTERT in residual benign meningiomas.
  • BACKGROUND: Relapse in individual patients after incomplete/residual removal of meningiomas cannot be predicted by histology alone as re-growth occurs even in histologically benign meningiomas.
  • MATERIALS AND METHODS: Proliferating cell nuclear antigen (PCNA), Ki-67 and human telomerase reverse transcriptase (hTERT) labelling indices were measured in histological sections derived from residual meningiomas in 37 patients to assess their relationship to relapse.
  • The histological specimens comprised the following 2 groups: (i) stable for at least 10 years after initial partial resection of residual meningiomas: 20 specimens;.
  • (ii) relapsing between 11 and 145 months after initial resection of residual meningiomas: 17 specimens.
  • CONCLUSION: The mean PCNA, Ki-67 and hTERT LI were higher in the relapsing group of residual meningiomas than in the stable group, although no statistical difference was found for PCNA and Ki-67.
  • On the other hand, a statistical difference between the two groups of meningiomas was found for hTERT; however, it is no absolute predictor for relapse at the individual patient level.
  • [MeSH-major] DNA-Binding Proteins / metabolism. Ki-67 Antigen / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Proliferating Cell Nuclear Antigen / metabolism. Telomerase / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16634530.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


66. Vranic A: Antigen expression on recurrent meningioma cells. Radiol Oncol; 2010 Jun;44(2):107-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antigen expression on recurrent meningioma cells.
  • INTRODUCTION: Meningiomas are intracranial brain tumours that frequently recur.
  • Recurrence rates up to 20% in 20 years for benign meningiomas, up to 80% for atypical meningiomas and up to 100% for malignant meningiomas, have been reported.
  • The most important prognostic factors for meningioma recurrence are meningioma grade, meningioma invasiveness and radicality of neurosurgical resection.
  • The aim of our study was to evaluate the differences in antigenic expression on the surface of meningioma cells between recurrent and non-recurrent meningiomas.
  • METHODS: 19 recurrent meningiomas and 35 non-recurrent meningiomas were compared regarding the expression of MIB-1 antigen, progesterone receptors, cathepsin B and cathepsin L, using immunohistochemistry.
  • RESULTS: MIB-1 antigen expression was higher in the recurrent meningioma group (p=0.001).
  • No difference in progesterone receptor status between recurrent and non-recurrent meningiomas was confirmed.
  • Immunohistochemical intensity scores for cathepsin B (p= 0.007) and cathepsin L (p<0.001) were both higher in the recurrent than in the non-recurrent meningioma group.
  • CONCLUSIONS: [corrected] MIB-1 antigen expression is higher in recurrent compared to non-recurrent meningiomas.
  • There is no difference in expression of progesterone receptors between recurrent and non-recurrent meningiomas.
  • Cathepsins B and L are expressed more in recurrent meningiomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1999 Jul;91(1):93-9 [10389886.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(9):921-32 [10526073.001]
  • [Cites] Neurosurgery. 2001 Mar;48(3):598-605 [11270551.001]
  • [Cites] J Neurosurg. 2001 Nov;95(5):839-44 [11702875.001]
  • [Cites] Cancer. 2002 Feb 1;94(3):765-72 [11857311.001]
  • [Cites] Histopathology. 2003 Sep;43(3):280-90 [12940781.001]
  • [Cites] J Neurooncol. 2003 Aug-Sep;64(1-2):71-6 [12952288.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):29-37 [15015767.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1547-53 [15735044.001]
  • [Cites] Int J Biol Markers. 2005 Jan-Mar;20(1):50-9 [15832773.001]
  • [Cites] Clin Neuropathol. 2005 Jul-Aug;24(4):170-4 [16033133.001]
  • [Cites] Neurosurgery. 2005 Sep;57(3):538-50; discussion 538-50 [16145534.001]
  • [Cites] Hum Pathol. 2006 Apr;37(4):415-21 [16564915.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2008 May;79(5):574-80 [17766430.001]
  • [Cites] Radiol Oncol. 2010 Mar;44(1):1-12 [22933884.001]
  • [Cites] Neuropathol Appl Neurobiol. 2004 Apr;30(2):178-87 [15043715.001]
  • [Cites] Am J Clin Pathol. 2003 Jan;119(1):123-8 [12520707.001]
  • [Cites] Acta Neurochir (Wien). 2004 Jan;146(1):37-44; discussion 44 [14740263.001]
  • [Cites] Surg Neurol. 1986 Nov;26(5):461-9 [3764651.001]
  • [Cites] J Neurosurg. 1995 Aug;83(2):285-90 [7542317.001]
  • [Cites] Clin Exp Metastasis. 1995 Jan;13(1):49-56 [7820956.001]
  • [Cites] Neurosurgery. 1993 Aug;33(2):212-7; discussion 217-8 [8367042.001]
  • [Cites] Neurosurgery. 1993 Apr;32(4):643-57 [8474655.001]
  • [Cites] Clin Exp Metastasis. 1996 Jan;14(1):27-34 [8521613.001]
  • [Cites] J Neurosurg. 1997 Jan;86(1):113-20 [8988089.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2262-9 [9610708.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):559-67 [10100707.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • (PMID = 22933900.001).
  • [ISSN] 1318-2099
  • [Journal-full-title] Radiology and oncology
  • [ISO-abbreviation] Radiol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovenia
  • [Other-IDs] NLM/ PMC3423683
  • [Keywords] NOTNLM ; cathepsin B / cathepsin L / meningioma / proliferation index, MIB-1 antigen / recurrence / tumour markers
  •  go-up   go-down


67. Pfisterer WK, Hendricks WP, Scheck AC, Nieman RA, Birkner TH, Krampla WW, Preul MC: Fluorescent in situ hybridization and ex vivo 1H magnetic resonance spectroscopic examinations of meningioma tumor tissue: is it possible to identify a clinically-aggressive subset of benign meningiomas? Neurosurgery; 2007 Nov;61(5):1048-59; discussion 1060-1
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescent in situ hybridization and ex vivo 1H magnetic resonance spectroscopic examinations of meningioma tumor tissue: is it possible to identify a clinically-aggressive subset of benign meningiomas?
  • OBJECTIVE: Although histologically benign, Grade I meningiomas can sometimes behave aggressively.
  • The clinically-aggressive subset of Grade I meningiomas is typically indistinguishable from clinically-benign Grade I meningiomas in vivo.
  • We compared molecular genetic and biochemical findings to clinical, pathological, and immunohistochemical information in a series of clinically-aggressive Grade I meningiomas with a series of clinically-benign meningiomas to identify characteristics that may be used to distinguish between these two groups.
  • METHODS: Tumor tissue samples from 30 patients with Grade I meningiomas were harvested.
  • RESULTS: Molecular genetic and biochemical findings correlated with clinical behavior of the two Grade I meningioma groups.
  • The presence of aberrations also influenced meningioma regrowth after subtotal resection.
  • Alanine was decreased in meningiomas with chromosomal aberrations in tumors that recurred.
  • CONCLUSION: Distinct molecular genetic and biochemical alterations differentiated clinically-aggressive Grade I meningiomas from clinically-benign Grade I meningiomas.
  • [MeSH-major] Biomarkers, Tumor / analysis. In Situ Hybridization, Fluorescence / methods. Magnetic Resonance Spectroscopy / methods. Meningioma / diagnosis. Meningioma / physiopathology. Neoplasm Proteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18091281.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Protons
  •  go-up   go-down


68. Wickremesekera A, Hovens CM, Kaye AH: Expression of ErbB-1 and ErbB-2 in meningioma. J Clin Neurosci; 2010 Sep;17(9):1155-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of ErbB-1 and ErbB-2 in meningioma.
  • Meningiomas are benign intracranial tumours treated by neurosurgical resection.
  • Effective molecular therapy for residual and recurrent meningiomas is currently unavailable.
  • We tested meningiomas for In-ErbB-1 and ErbB-2, and the levels were compared to normal brain, peripheral nerve, glioblastoma multiforme and vestibular schwannoma.
  • These preliminary results implicate a potential role for ErbB-2 in the benign tumourigenesis of meningioma consistent with the theoretical hierarchical interactions of homodimers of ErbB-2 that may be associated with low signal transduction.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Receptor, Epidermal Growth Factor / biosynthesis. Receptor, ErbB-2 / biosynthesis

  • Genetic Alliance. consumer health - Meningioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20547458.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


69. Elia AE, Shih HA, Loeffler JS: Stereotactic radiation treatment for benign meningiomas. Neurosurg Focus; 2007;23(4):E5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic radiation treatment for benign meningiomas.
  • Meningiomas are the second most common primary tumor of the brain.
  • For incompletely resected or inoperable benign meningiomas, 3D conformal external-beam radiation therapy can provide durable local tumor control in 90 to 95% of cases.
  • Stereotactic radiosurgery has been used as an alternative or adjuvant therapy to surgery for meningiomas in locations, such as the skull base, where operative manipulation may be particularly difficult.
  • Stereotactic radiotherapy is useful for larger meningiomas (> 3-3.5 cm) and those closely approximating critical structures, such as the optic chiasm and brainstem.
  • Although SRS has longer follow-up than SRT, both techniques have excellent 5-year tumor control rates of greater than 90% for benign meningiomas.
  • Stereotactic radiotherapy has toxicity equivalent to that of radiosurgery, despite its biased use for larger meningiomas with more complicated volumes.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / pathology. Meningioma / surgery. Radiosurgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961042.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 47
  •  go-up   go-down


70. Wibom C, Mörén L, Aarhus M, Knappskog PM, Lund-Johansen M, Antti H, Bergenheim AT: Proteomic profiles differ between bone invasive and noninvasive benign meningiomas of fibrous and meningothelial subtype. J Neurooncol; 2009 Sep;94(3):321-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic profiles differ between bone invasive and noninvasive benign meningiomas of fibrous and meningothelial subtype.
  • Meningiomas of WHO grade I can usually be cured by surgical resection.
  • However, some tumors may, despite their benign appearance, display invasive growth behavior.
  • By histology alone, bone invasive meningiomas may be indistinguishable from their noninvasive counterparts.
  • In this study we have examined the protein spectra in a series of meningiomas in search of protein expression patterns that may distinguish between bone invasive and noninvasive meningiomas.
  • Tumor tissue from 13 patients with fibrous (6 invasive and 7 noninvasive) and 29 with meningothelial (10 invasive and 19 noninvasive) grade I meningiomas were analyzed by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI).
  • Comparing the protein spectra from invasive and noninvasive fibrous meningioma we found 22 peaks whose intensities were significantly different between the two groups (P < 0.001).
  • In meningothelial meningioma the same comparison yielded six significantly differentially expressed peaks (P < 0.001), which to a large degree separated the invasive from noninvasive tissue (area under ROC curve = 0.873).
  • By analyzing the protein spectra in benign meningiomas we could differentiate between invasive and noninvasive growth behavior in both fibrous and meningothelial meningiomas of grade I.
  • A possibility for early identification of invasive grade I meningiomas may have a strong influence on the follow-up policy and the issue of early or late radiotherapy.
  • [MeSH-major] Bone Neoplasms / metabolism. Bone Neoplasms / secondary. Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Invasiveness / pathology. Proteomics

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19350207.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


71. Bledsoe JM, Link MJ, Stafford SL, Park PJ, Pollock BE: Radiosurgery for large-volume (&gt; 10 cm3) benign meningiomas. J Neurosurg; 2010 May;112(5):951-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiosurgery for large-volume (> 10 cm3) benign meningiomas.
  • OBJECT: Stereotactic radiosurgery (SRS) has proven to be a safe and effective treatment for many patients with intracranial meningiomas.
  • Nevertheless, the morbidity associated with radiosurgery of larger meningiomas is poorly understood.
  • METHODS: The authors performed a retrospective review of 116 patients who underwent SRS for meningiomas (WHO Grade I) > 10 cm3 between 1990 and 2007, with a minimum follow-up of 12 months.
  • Patients with atypical or malignant meningiomas and those who received prior radiotherapy were excluded.
  • CONCLUSIONS: The morbidity associated with SRS for patients with benign meningiomas > 10 cm(3) is greater for supratentorial tumors compared with skull base tumors.
  • Whereas radiosurgery is relatively safe for patients with large-volume skull base meningiomas, resection should remain the primary disease management for the majority of patients with large-volume supratentorial meningiomas.
  • [MeSH-major] Meningioma / pathology. Meningioma / surgery. Radiosurgery / instrumentation. Skull Base Neoplasms / pathology. Skull Base Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg. 2010 Dec;113(6):1335-6; author reply 1336-7 [20887089.001]
  • (PMID = 19764829.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Lusis EA, Watson MA, Chicoine MR, Lyman M, Roerig P, Reifenberger G, Gutmann DH, Perry A: Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. Cancer Res; 2005 Aug 15;65(16):7121-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma.
  • Although meningiomas are common central nervous system tumors, little is known about the genetic events responsible for malignant progression.
  • In this study, we employed gene expression profiling to identify transcripts whose expression was lost in anaplastic (WHO grade III) versus benign (WHO grade I) meningioma.
  • Approximately 40% of genes down-regulated in anaplastic meningioma were localized to chromosomes 1p and 14q.
  • One specific gene located at 14q11.2, NDRG2, was consistently down-regulated in grade III meningioma, a finding which we validated at both the transcript and protein levels in independent sets of clinically and pathologically diverse meningiomas.
  • Loss of NDRG2 expression was also seen in a subset of lower-grade meningiomas, including atypical meningiomas (WHO grade II) with clinically aggressive behavior.
  • Collectively, these data identify NDRG2 as the first specific candidate tumor suppressor gene on chromosome 14q that is inactivated during meningioma progression.
  • In addition, these findings highlight the utility of combining genomic, epigenetic, and expression data to identify clinically significant tumor biomarkers, and suggest that NDRG2 expression will be a useful and functionally relevant biomarker to predict aggressive behavior in patients with meningioma.
  • [MeSH-major] Genes, Tumor Suppressor. Meningeal Neoplasms / genetics. Meningioma / genetics. Proteins / genetics

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16103061.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NDRG2 protein, human; 0 / Proteins; 0 / RNA, Messenger; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


73. Ohba S, Yoshida K, Hirose Y, Ikeda E, Kawase T: Early malignant transformation of a petroclival meningothelial meningioma. Neurosurg Rev; 2009 Oct;32(4):495-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early malignant transformation of a petroclival meningothelial meningioma.
  • Although some authors have reported the malignant transformation of meningiomas, there has been no previous report describing that a meningothelial meningioma transformed into an atypical meningioma within 1 year.
  • This report documents a 57-year-old woman who presented with right hearing disturbance.
  • Magnetic resonance imaging revealed a right petroclival meningioma.
  • The tumor was subtotally removed and was diagnosed to be a meningothelial meningioma.
  • The diagnosis of this recurrent tumor was an atypical meningioma.
  • These results suggest that the present case had a potentially malignant tumor in the early stage, although it had the histological features of benign meningiomas.
  • An evaluation of the MIB-1 index, as well as the expression of p53 and chromosomal aberrations, may be useful for predicting the malignant transformation of meningiomas.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Diagn Pathol. 2003 Aug;7(4):214-22 [12913843.001]
  • [Cites] Cell. 1998 Oct 2;95(1):5-8 [9778240.001]
  • [Cites] Hum Pathol. 2001 Sep;32(9):970-5 [11567227.001]
  • [Cites] Cancer Res. 1998 Jan 1;58(1):29-33 [9426052.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Jan 15;148(2):148-51 [14734228.001]
  • [Cites] J Neurooncol. 1999 Jan;41(2):167-74 [10222437.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Jun;60(6):628-36 [11398839.001]
  • [Cites] Oncogene. 1991 Aug;6(8):1313-8 [1886708.001]
  • [Cites] Neurosurgery. 2005 Sep;57(3):538-50; discussion 538-50 [16145534.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2262-9 [9610708.001]
  • [Cites] Science. 1997 Mar 28;275(5308):1943-7 [9072974.001]
  • [Cites] J Neurosurg. 1985 Dec;63(6):857-61 [4056899.001]
  • [Cites] Cancer Res. 1993 May 15;53(10 Suppl):2386-92 [8485725.001]
  • [Cites] Neuropathol Appl Neurobiol. 2000 Feb;26(1):67-75 [10736068.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Apr 15;110(2):103-10 [10214357.001]
  • [Cites] Int J Cancer. 1994 Feb 1;56(3):354-7 [8314321.001]
  • [Cites] Cytogenet Cell Genet. 2001;93(3-4):207-20 [11528114.001]
  • [Cites] Oncogene. 1999 Apr 1;18(13):2231-9 [10327069.001]
  • [Cites] Hum Pathol. 1998 Feb;29(2):140-5 [9490273.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] Neuropathol Appl Neurobiol. 1995 Apr;21(2):136-42 [7609844.001]
  • [Cites] J Neurosurg. 1989 Nov;71(5 Pt 1):665-72 [2809720.001]
  • [Cites] J Neurosurg. 2007 Aug;107(2):398-404 [17695396.001]
  • [Cites] J Neurosurg. 2004 Aug;101(2):210-8 [15309910.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7121-6 [16103061.001]
  • [Cites] J Mol Diagn. 2001 May;3(2):62-7 [11333301.001]
  • [Cites] J Med Genet. 2006 Mar;43(3):285-7 [15980114.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3569-77 [10589773.001]
  • (PMID = 19533187.001).
  • [ISSN] 1437-2320
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; 9007-49-2 / DNA
  •  go-up   go-down


74. Rao S, Sadiya N, Doraiswami S, Prathiba D: Characterization of morphologically benign biologically aggressive meningiomas. Neurol India; 2009 Nov-Dec;57(6):744-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of morphologically benign biologically aggressive meningiomas.
  • BACKGROUND: Meningiomas are presently categorized into three grades by World Health Organization (WHO).
  • Grade I, in general, is expected to behave in a benign fashion.
  • However, a borderline group of grade I meningioma also exists, which may behave aggressively.
  • AIMS AND OBJECTIVE: To evaluate the proliferation index and p53 antigen expression of meningiomas and correlate with histological grade and clinical course.
  • MATERIALS AND METHODS: All 123 cases of meningiomas, diagnosed between January 2000 and August 2007, were regraded according to WHO 2000 criteria.
  • Mean Ki-67 labeling index (Ki-67 LI) was 3.8%, 13.7%, 19.4% for grade I, II, and III cases, respectively.
  • Mean p53 expression was found to be 15.5%, 57%, 60.8%, and 62.5% for grade I, II, III, and recurrent cases, respectively.
  • All recurrent cases were histologically WHO grade I, and showed a high Ki-67 LI and p53 expression with mean Ki-67 LI and p53 expression of 8.6% and 62.5% respectively.
  • CONCLUSION: Utilization of markers for proliferation and cell cycle regulators in combination with histopathological features helps in the identification of a subset of biologically aggressive morphologically benign meningiomas.
  • [MeSH-major] Ki-67 Antigen / metabolism. Meningeal Neoplasms / metabolism. Meningeal Neoplasms / pathology. Meningioma / metabolism. Meningioma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20139503.001).
  • [ISSN] 0028-3886
  • [Journal-full-title] Neurology India
  • [ISO-abbreviation] Neurol India
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


75. Yue Q, Isobe T, Shibata Y, Anno I, Kawamura H, Yamamoto Y, Takano S, Matsumura A: New observations concerning the interpretation of magnetic resonance spectroscopy of meningioma. Eur Radiol; 2008 Dec;18(12):2901-11
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New observations concerning the interpretation of magnetic resonance spectroscopy of meningioma.
  • This study was aimed to clarify some ambiguities in the interpretation of proton magnetic resonance spectroscopy (1H-MRS) of meningiomas.
  • The cases of 31 meningioma patients (27 benign and 4 nonbenign meningiomas) that underwent single-voxel 1H-MRS (PRESS sequence, TR/TE = 2,000 ms/68, 136, 272 ms) were retrospectively analyzed.
  • All meningiomas demonstrated increased choline and decreased creatine, except for a lipomatous meningioma that only displayed a prominent lipid (Lip) peak.
  • Alanine (Ala) and lactate (Lac) coexisted in eight cases, indicating an alternative pathway of energy metabolism in meningiomas.
  • Glutamine/glutamate (Glx) was helpful for the recognition of meningioma when Ala was absent.
  • N-acetyl compounds(NACs) were observed in nine cases whose voxels were completely limited within the tumors, indicating that meningiomas might have endogenous NACs.
  • Lac was indicative of an aggressive meningioma, although not always a nonbenign one.
  • Lip not only represented micronecrosis in nonbenign meningiomas, but also reflected microcystic changes or fatty degeneration in benign meningiomas.
  • 1H-MRS reflects some distinctive biochemical and pathological changes of meningiomas that might be misinterpreted.
  • [MeSH-major] Biomarkers, Tumor / analysis. Choline / analysis. Creatine / analysis. Magnetic Resonance Spectroscopy / methods. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / metabolism. Meningioma / diagnosis. Meningioma / metabolism

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CREATINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] NMR Biomed. 2001 Aug;14(5):307-17 [11477651.001]
  • [Cites] NMR Biomed. 1991 Apr;4(2):85-9 [1650244.001]
  • [Cites] J Neurosurg. 2001 Jan;94(1):55-60 [11147898.001]
  • [Cites] Radiology. 1989 Aug;172(2):541-8 [2748837.001]
  • [Cites] Neurosurgery. 2007 Nov;61(5):1048-59; discussion 1060-1 [18091281.001]
  • [Cites] Magn Reson Med. 2003 Apr;49(4):632-7 [12652533.001]
  • [Cites] Radiology. 1993 Mar;186(3):745-52 [8430183.001]
  • [Cites] Neuroradiology. 2007 Feb;49(2):121-7 [17086406.001]
  • [Cites] NMR Biomed. 1997 Jan;10(1):2-12 [9251109.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6408-13 [9177231.001]
  • [Cites] Magn Reson Imaging. 1995;13(7):1019-29 [8583866.001]
  • [Cites] Eur J Radiol. 2006 Oct;60(1):48-55 [16844335.001]
  • [Cites] Neurol Res. 2007 Jan;29(1):43-6 [17427274.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10 ):3983-93 [11051247.001]
  • [Cites] Magn Reson Med. 2003 Feb;49(2):223-32 [12541241.001]
  • [Cites] AJNR Am J Neuroradiol. 1982 May-Jun;3(3):267-76 [6805276.001]
  • [Cites] Am J Surg Pathol. 2001 Jun;25(6):769-75 [11395554.001]
  • [Cites] J Neurol. 1996 Oct;243(10):706-14 [8923303.001]
  • [Cites] Radiology. 1992 Jun;183(3):701-9 [1584924.001]
  • [Cites] Magn Reson Imaging. 1995;13(6):853-69 [8544657.001]
  • [Cites] Neuroradiology. 2003 Mar;45(3):129-36 [12684713.001]
  • [Cites] Neuroradiology. 2002 Jul;44(7):574-8 [12136358.001]
  • [Cites] J Comput Assist Tomogr. 1994 Sep-Oct;18(5):705-13 [8089316.001]
  • [Cites] J Neurosurg. 1999 Dec;91(6):928-34 [10584837.001]
  • [Cites] Neurosurgery. 2005 Dec;57(6):1088-95; discussion 1088-95 [16331155.001]
  • [Cites] J Neurosurg. 1996 Mar;84(3):449-58 [8609557.001]
  • [Cites] Magn Reson Imaging. 1993;11(1):107-18 [8423713.001]
  • [Cites] NMR Biomed. 1991 Apr;4(2):47-52 [1650241.001]
  • [Cites] Eur Radiol. 2003 Mar;13(3):582-91 [12594562.001]
  • [Cites] NMR Biomed. 2005 Oct;18(6):371-82 [15959923.001]
  • [Cites] NMR Biomed. 1992 Jan-Feb;5(1):43-7 [1550709.001]
  • [Cites] Neurosurgery. 1987 May;20(5):688-94 [3601014.001]
  • [Cites] Magn Reson Imaging. 2003 Jul;21(6):663-72 [12915198.001]
  • [Cites] Nervenarzt. 2005 Apr;76(4):403-17 [15349736.001]
  • [Cites] Neurosurgery. 1994 Oct;35(4):606-13; discussion 613-4 [7808603.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Jan;17(1):1-15 [8770242.001]
  • [Cites] J Neurooncol. 2000 Apr;47(2):99-108 [10982150.001]
  • [Cites] Clin Neuropathol. 1988 Jan-Feb;7(1):16-21 [3370860.001]
  • (PMID = 18641997.001).
  • [ISSN] 1432-1084
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Protons; MU72812GK0 / Creatine; N91BDP6H0X / Choline
  •  go-up   go-down


76. Okamoto H, Li J, Vortmeyer AO, Jaffe H, Lee YS, Gläsker S, Sohn TS, Zeng W, Ikejiri B, Proescholdt MA, Mayer C, Weil RJ, Oldfield EH, Zhuang Z: Comparative proteomic profiles of meningioma subtypes. Cancer Res; 2006 Oct 15;66(20):10199-204
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative proteomic profiles of meningioma subtypes.
  • Meningiomas are classified into three groups (benign, atypical, and anaplastic) based on morphologic characteristics.
  • Atypical meningiomas, which are WHO grade 2 tumors, and anaplastic meningiomas, which are WHO grade 3 tumors, exhibit an increased risk of recurrence and premature death compared with benign WHO grade 1 tumors.
  • Although atypical and anaplastic meningiomas account for <10% of all of meningiomas, it can be difficult to distinguish them from benign meningiomas by morphologic criteria alone.
  • We used selective tissue microdissection to examine 24 human meningiomas and did two-dimensional gel electrophoresis to determine protein expression patterns.
  • Proteins expressed differentially by meningiomas of each WHO grade were identified and sequenced.
  • Proteomic analysis revealed protein expression patterns unique to WHO grade 1, 2, and 3 meningiomas and identified 24 proteins that distinguish each subtype.
  • Fifteen proteins showed significant changes in expression level between benign and atypical meningiomas, whereas nine distinguished atypical from anaplastic meningiomas.
  • We established differential proteomic profiles that characterize and distinguish meningiomas of increasing grades.
  • The proteins and proteomic profiles enhance understanding of the pathogenesis of meningiomas and have implications for diagnosis, prognosis, and treatment.
  • [MeSH-major] Meningeal Neoplasms / classification. Meningioma / classification

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17047085.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  •  go-up   go-down


77. Lee JH, Sade B, Choi E, Golubic M, Prayson R: Meningothelioma as the predominant histological subtype of midline skull base and spinal meningioma. J Neurosurg; 2006 Jul;105(1):60-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningothelioma as the predominant histological subtype of midline skull base and spinal meningioma.
  • OBJECT: This study was undertaken to test a hypothesis that meningiomas of the midline skull base and spine are predominantly of the meningothelial histological subtype.
  • METHODS: The cases of 794 consecutive patients who underwent resection for meningioma at the Cleveland Clinic between January 1991 and March 2004 were reviewed retrospectively.
  • The authors analyzed the relationship between the tumors' histological subtypes and sites of origin in the 731 patients from this group who harbored tumors that were determined to be benign histologically (World Health Organization Grade I).
  • Meningothelial meningiomas (MMs) accounted for 63.5% (464/731) of the Grade I tumors.
  • CONCLUSIONS: Meningiomas of the midline neuraxis are predominantly meningotheliomas.
  • Analysis of the increasingly available data on genetic and topographic characteristics of MMs suggests that they may represent a unique entity, contrary to the prevailing belief that all benign meningiomas are identical tumors.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology. Skull Base Neoplasms / pathology. Spinal Cord Neoplasms / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Meningioma, spinal.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16871881.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Davidson L, Fishback D, Russin JJ, Weiss MH, Yu C, Pagnini PG, Zelman V, Apuzzo ML, Giannotta SL: Postoperative Gamma Knife surgery for benign meningiomas of the cranial base. Neurosurg Focus; 2007;23(4):E6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative Gamma Knife surgery for benign meningiomas of the cranial base.
  • OBJECT: The standard treatment for meningiomas is complete resection, but the proximity of skull base meningiomas to important neurovascular structures makes complete excision of the lesion difficult or impossible.
  • The authors analyzed the mid- and long-term results obtained in patients treated with postresection Gamma Knife surgery (GKS) for residual or recurrent benign meningiomas of the cranial base.
  • METHODS: Thirty-six patients with residual or recurrent benign meningiomas of the skull base following one or more surgical procedures underwent GKS.
  • It should be initially considered along with surgery for the treatment of complex skull base meningiomas.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Radiosurgery. Skull Base Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961043.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Couldwell WT, Cole CD, Al-Mefty O: Patterns of skull base meningioma progression after failed radiosurgery. J Neurosurg; 2007 Jan;106(1):30-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of skull base meningioma progression after failed radiosurgery.
  • OBJECT: Stereotactic radiosurgery has been reported to be an effective alternative to surgical removal of small to medium benign meningiomas as well as an adjuvant treatment modality to reduce the risk of tumor progression after subtotal resection.
  • Little is known, however, regarding the growth patterns of meningiomas that fail to stabilize after radiosurgery.
  • METHODS: The authors report 13 cases of benign skull base meningiomas (World Health Organization Grade I) that demonstrated progression after radiosurgical treatment as a primary or an adjuvant therapy.
  • CONCLUSIONS: Skull base meningioma growth can be aggressive after failed radiosurgery in some patients, and treatment failure can occur at long intervals following treatment.
  • Special attention must be devoted to such significant occurrences given the increasing number of patients undergoing stereotactic radiosurgery for benign tumors, and careful extended (> 10 years) follow up must be undertaken in all patients after radiosurgery.
  • [MeSH-major] Meningioma / pathology. Meningioma / surgery. Radiosurgery. Skull Base Neoplasms / pathology. Skull Base Neoplasms / surgery

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17236485.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Sacko O, Rabarijaona M, Loiseau H: [Spinal meningioma surgery after 75 years of age]. Neurochirurgie; 2008 Aug;54(4):512-6
Genetic Alliance. consumer health - Meningioma, spinal.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Spinal meningioma surgery after 75 years of age].
  • BACKGROUND AND PURPOSE: Spinal meningioma surgery is usually not difficult and is commonly associated with good outcome.
  • Therefore, we attempted to assess the surgical outcome of spinal meningiomas in the elderly and to analyze the role of outcome predictors.
  • METHODS: From 1990 to 2006, 32 patients 76 years or older with spinal meningiomas were operated on in our Neurosurgery Departments.
  • One patient was rated Solero grade I, 11 grade II, 17 grade III and three patients were rated grade IV.
  • All meningiomas were benign.
  • CONCLUSIONS: Surgery is the only treatment of symptomatic spinal meningioma.
  • [MeSH-major] Meningioma / surgery. Spinal Cord Neoplasms / surgery

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18495178.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


81. Samadi N, Ahmadi SA: Meningioma: a clinicopathological evaluation. Malays J Med Sci; 2007 Jan;14(1):46-52

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningioma: a clinicopathological evaluation.
  • As yet no unifying grading system for meningiomas has been adopted.
  • We evaluate epidemiologic factors of meningioma in Iran & degree of agreement between the two commonly used grading systems namely WHO (2000) and Mahmood systems.
  • During a 6-year period 238 meningiomas were selected and reviewed by two independent pathologists using both grading systems.
  • 205(86.1%) cases were benign, 19(8%) atypical and 14(5.9%) malignant.
  • 181(18%) cases were primary and 51(27%) secondary; 35(68%) of the latter benign, 7(14%) atypical and 9(18%) malignant.
  • All intraspinal meningiomas were benign.
  • In benign cranial and spinal types female to male ratios were 1.9: 1 and 1.3: 1 ; while in atypical and malignant types were 1 :1.4 and 1:3.1 respectively.
  • Mean ages were 49.9 for benign.
  • Female preponderance seen in benign nonrecurrent meningioma became increasingly less prominent and even reversed in recurrent, atypical and malignant forms.
  • Benign recurrent tumors were similar to non-recurrent tumors microscopically.
  • Kappa value comparing two grading systems was 0.947, so good agreements were found between Mahmood and WHO grading systems.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Sep 1;89(5):1102-10 [10964341.001]
  • [Cites] Neurol India. 2000 Dec;48(4):338-42 [11146597.001]
  • [Cites] J Pathol. 2001 Jul;194(3):367-72 [11439370.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Oct;60(10):994-1003 [11589430.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1538-47 [11920512.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • [Cites] Neurosurgery. 1993 Dec;33(6):955-63 [8134008.001]
  • [Cites] J Cutan Pathol. 1994 Dec;21(6):549-56 [7699122.001]
  • [Cites] Am J Med Genet. 1994 Oct 1;52(4):450-61 [7747758.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1455-65 [9414189.001]
  • [Cites] J Neurosurg. 1998 Mar;88(3):562-9 [9488313.001]
  • [Cites] J Med Genet. 1992 Dec;29(12):841-6 [1479598.001]
  • (PMID = 22593651.001).
  • [ISSN] 1394-195X
  • [Journal-full-title] The Malaysian journal of medical sciences : MJMS
  • [ISO-abbreviation] Malays J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Malaysia
  • [Other-IDs] NLM/ PMC3351217
  • [Keywords] NOTNLM ; Mahmood grading system / WHO grading system / brain tumor / intracranial / intraspinal / meningioma
  •  go-up   go-down


82. Al-Khalaf HH, Lach B, Allam A, AlKhani A, Alrokayan SA, Aboussekhra A: The p53/p21 DNA damage-signaling pathway is defective in most meningioma cells. J Neurooncol; 2007 May;83(1):9-15
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The p53/p21 DNA damage-signaling pathway is defective in most meningioma cells.
  • Although meningiomas represent the most common class of tumors of the central nervous system, the molecular events underlying their genesis and development are still not well defined.
  • In the present study we have used the immuno-blotting technique to study the expression level of the tumor suppressor proteins p53, p21 and PTEN in primary meningioma cells.
  • These results suggest that the tumor suppressors p53/p21 signaling pathway and PTEN play important roles in the development of benign meningiomas.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p21 / genetics. DNA Damage. Genes, p53. Meningeal Neoplasms / genetics. Meningioma / genetics. Signal Transduction

  • Genetic Alliance. consumer health - Meningioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17245624.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Membrane Proteins; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 3.1.3.48 / TPTE protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


83. Colombo F, Casentini L, Cavedon C, Scalchi P, Cora S, Francescon P: Cyberknife radiosurgery for benign meningiomas: short-term results in 199 patients. Neurosurgery; 2009 Feb;64(2 Suppl):A7-13

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyberknife radiosurgery for benign meningiomas: short-term results in 199 patients.
  • OBJECTIVE: To present initial, short-term results obtained with an image-guided radiosurgery apparatus (CyberKnife; Accuray, Inc., Sunnyvale, CA) in a series of 199 benign intracranial meningiomas.
  • CONCLUSION: The introduction of the CyberKnife extended the indication to 63 patients (>30%) who could not have been treated by single-session radiosurgical techniques.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Radiosurgery / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19165077.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Lah TT, Nanni I, Trinkaus M, Metellus P, Dussert C, De Ridder L, Rajcević U, Blejec A, Martin PM: Toward understanding recurrent meningioma: the potential role of lysosomal cysteine proteases and their inhibitors. J Neurosurg; 2010 May;112(5):940-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toward understanding recurrent meningioma: the potential role of lysosomal cysteine proteases and their inhibitors.
  • OBJECT: The first aim of this study was to diagnose more aggressive and potentially recurrent meningiomas using an in vitro embryonic chick heart invasiveness assay in which lysosomal enzyme cathepsin B was used as the invasiveness marker.
  • The second aim was to confirm if cathepsin B and/or cathepsin L and their endogenous inhibitors were also prognostic parameters in the clinical study of 119 patients with meningioma.
  • METHODS: Primary meningioma cultured spheroids were "confronted" with embryonic chick heart spheroids in vitro, and cathepsin B was used as molecular marker to immunolabel the invasive tumor cells.
  • In vitro invasion assays of the malignant meningioma cells were used to assess the invasive potential related to the cysteine cathepsins.
  • As to the second aim, the possible association of cathepsin B along with selected molecular markers, cathepsin L, and endogenous cysteine protease inhibitors (stefins A and B and cystatin C) with meningioma malignancy was determined using enzyme-linked immunosorbent assays in tumor homogenates.
  • Univariate and multivariate analyses were used to compare these parameters with established biological markers of meningioma recurrence in 119 patients with meningiomas.
  • RESULTS: The more invasive tumors, which characteristically overgrew the normal tissue, were identified even within a group of histologically benign meningiomas.
  • Matrigel invasion of malignant meningioma cells was significantly altered by modulating cathepsin B activity and by stefin B silencing.
  • In the clinical samples of meningioma, the levels of cathepsins B and L, stefin B, and cystatin C were highest in the tumors of higher histological grades, whereas stefin A and progesterone receptor were the only markers that were significantly increased and decreased, respectively, in WHO Grade III lesions.
  • As expected, WHO grade, age, and Simpson grade (complete tumor resection) were prognostic, with Simpson grade only relevant in the short term (up to 90 months) but not in longer-term follow-up.
  • CONCLUSIONS: The data indicate that the cysteine cathepsins and their inhibitors are involved in a process related to early meningioma recurrence, regardless of their histological classification.
  • Of note, the known tumor invasiveness marker cathepsin B, measured in whole-tumor homogenates, was not prognostic, in contrast to its endogenous inhibitor stefin B, which was highly significant and the only independent prognostic factor to predict meningioma relapse in multivariate analysis and reported herein for the first time.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Neoplasms / pathology. Cysteine Proteinase Inhibitors / pharmacology. Cysteine Proteinase Inhibitors / therapeutic use. Lysosomes / drug effects. Meningioma / drug therapy. Meningioma / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19747051.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CSTB protein, human; 0 / Cystatin A; 0 / Cysteine Proteinase Inhibitors; 88844-95-5 / Cystatin B; EC 3.4.22.1 / CTSB protein, human; EC 3.4.22.1 / Cathepsin B
  •  go-up   go-down


85. Bhadra AK, Casey AT, Saifuddin A, Briggs TW: Primary atypical sacral meningioma--not always benign. Skeletal Radiol; 2007 Jun;36 Suppl 1:S91-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary atypical sacral meningioma--not always benign.
  • We present a case of an atypical recurrent meningioma of the sacrum with pulmonary metastasis in a 31-year-old man.
  • Histology confirmed atypical meningioma.
  • [MeSH-major] Lung Neoplasms / secondary. Meningioma / pathology. Sacrococcygeal Region / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17096157.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


86. Zada G, Pagnini PG, Yu C, Erickson KT, Hirschbein J, Zelman V, Apuzzo ML: Long-term outcomes and patterns of tumor progression after gamma knife radiosurgery for benign meningiomas. Neurosurgery; 2010 Aug;67(2):322-8; discussion 328-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes and patterns of tumor progression after gamma knife radiosurgery for benign meningiomas.
  • OBJECT: To characterize the timing and patterns of long-term treatment failure after Gamma Knife radiosurgery (GKRS) for benign meningiomas.
  • METHODS: Data were retrospectively reviewed in 116 patients who underwent 136 GKRS treatments for benign intracranial meningiomas from 1996 to 2004.
  • Patients with atypical or malignant meningiomas were excluded.
  • CONCLUSIONS: GKRS demonstrates excellent long-term tumor control in the management of benign meningiomas.
  • [MeSH-major] Meningioma / pathology. Meningioma / surgery. Radiosurgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20644417.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Ferchichi L, Bellil S, Ben Hammouda K, Bellil K, Mekni A, Bettaieb I, Haouet S, Khaldi MM, Zitouna K, Kchir N: Anaplastic secretory meningioma: a case report. Pathologica; 2006 Apr;98(2):153-5
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic secretory meningioma: a case report.
  • Secretory meningiomas are rare histological subtypes of meningiomas with benign biological behaviour.
  • In this study, the authors describe the first case of secretory meningioma with many mitotic figures and brain invasion, and discuss the clinicopathologic features including immunohistochemical staining profile and ultrastructural appearance of this tumour.
  • The histological diagnosis was secretory meningioma with many mitotic figures, a high MIB-1 labeling index and a brain invasion.
  • [MeSH-major] Frontal Lobe / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16929789.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Ki-67 Antigen; 0 / Mucin-1; 0 / Neoplasm Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


88. Simis A, Pires de Aguiar PH, Leite CC, Santana PA Jr, Rosemberg S, Teixeira MJ: Peritumoral brain edema in benign meningiomas: correlation with clinical, radiologic, and surgical factors and possible role on recurrence. Surg Neurol; 2008 Nov;70(5):471-7; discussion 477
Genetic Alliance. consumer health - Edema.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritumoral brain edema in benign meningiomas: correlation with clinical, radiologic, and surgical factors and possible role on recurrence.
  • BACKGROUND: Approximately 60% of meningiomas are associated with peritumoral edema.
  • The objective of this study was to investigate the correlation of PTBE with clinical, radiologic, and surgical aspects and recurrence of meningiomas.
  • METHODS: Sixty-one patients with benign meningiomas were chosen for surgical treatment by the Group of Brain Tumors and Metastasis of the Department of Neurosurgery.
  • Meningiomas with larger edema sizes also showed correlation with large meningiomas (P = .035), and the ones with smaller edema sizes correlated with the tentorial location (P = .032).
  • Multivariate analysis showed an association between PTBE and the presence of seizures (odds ratio, 3.469), large meningiomas (odds ratio, 15.977), and for each cubic centimeter added to its size, the risk of edema increased 1.082 times (odds ratio).
  • CONCLUSION: Peritumoral brain edema may be related to the invading potential of meningiomas and may play a role in the recurrence potential of the tumor.
  • As a consequence, it is reasonable to consider the presence of edema as an additional factor to be taken into account when mapping out strategies for the treatment of meningiomas.
  • [MeSH-major] Brain Edema / complications. Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / pathology. Meningioma / surgery. Neoplasm Recurrence, Local / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18586307.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Dijkstra M, van Nieuwenhuizen D, Stalpers LJ, Wumkes M, Waagemans M, Vandertop WP, Heimans JJ, Leenstra S, Dirven CM, Reijneveld JC, Klein M: Late neurocognitive sequelae in patients with WHO grade I meningioma. J Neurol Neurosurg Psychiatry; 2009 Aug;80(8):910-5
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late neurocognitive sequelae in patients with WHO grade I meningioma.
  • BACKGROUND: Information on neurocognitive outcome following treatment of benign meningiomas is virtually lacking.
  • The aim of the present study was therefore to document the extent and nature of neurocognitive deficits in patients with World Health Organization (WHO) grade I meningioma after treatment.
  • METHODS: 89 patients with WHO grade I meningioma who underwent surgery with or without adjuvant radiotherapy were individually matched to 89 healthy controls for age, sex and educational level.
  • RESULTS: Compared with healthy controls, patients with meningioma showed significant impairments in executive functioning (p<0.001), verbal memory (p<0.001), information processing capacity (p = 0.001), psychomotor speed (p = 0.001) and working memory (p = 0.006).
  • Patients with skull base meningiomas performed significantly lower on three out of six neurocognitive domains compared with convexity meningiomas.
  • Left-sided as opposed to right-sided meningiomas were related to verbal memory deficits.
  • CONCLUSIONS: Meningioma patients are characterised by long term deficits in neurocognitive functioning that can partly be attributed to the use of antiepileptic drugs and tumour location but not to the use of radiotherapy.
  • [MeSH-major] Cognition Disorders / etiology. Meningioma / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18653549.001).
  • [ISSN] 1468-330X
  • [Journal-full-title] Journal of neurology, neurosurgery, and psychiatry
  • [ISO-abbreviation] J. Neurol. Neurosurg. Psychiatr.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


90. Guevara P, Escobar-Arriaga E, Saavedra-Perez D, Martinez-Rumayor A, Flores-Estrada D, Rembao D, Calderon A, Sotelo J, Arrieta O: Angiogenesis and expression of estrogen and progesterone receptors as predictive factors for recurrence of meningioma. J Neurooncol; 2010 Jul;98(3):379-84
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiogenesis and expression of estrogen and progesterone receptors as predictive factors for recurrence of meningioma.
  • Meningiomas are benign tumors, with low rate of recurrence after surgery.
  • Angiogenesis, an important substratum for growth and spread of neoplasic cells, and the expression of estrogen and progesterone receptors (ER, PR), could play a role in the recurrence of meningioma.
  • We evaluated 42 patients with meningioma diagnosis (confirmed by histopathology) treated exclusively by surgery between January 1995 and December 1999, and compared the recurring and non-recurring groups after a ten-year follow-up period.
  • Recurrence of meningioma was found in 17 patients (40%).
  • The most important factor associated with meningioma relapse was vascular density, independently of hormonal status and extent of surgical resection.
  • [MeSH-major] Meningeal Neoplasms / metabolism. Meningioma / metabolism. Neoplasm Recurrence, Local / diagnosis. Neovascularization, Pathologic / etiology. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20013146.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin E; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


91. Vogelbaum MA, Leland Rogers C, Linskey MA, Mehta MP: Opportunities for clinical research in meningioma. J Neurooncol; 2010 Sep;99(3):417-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Opportunities for clinical research in meningioma.
  • Meningiomas, when benign, are commonly treated with surgical resection alone.
  • However, the optimal treatment for patients with subtotally resected or recurrent World Health Organization (WHO) grade I tumors, or WHO grade II and III tumors, regardless of the extent of resection, is not well defined, with both a paucity of high quality published evidence as well as a perceived minimal clinical effect for currently available interventions, specifically in terms of prolonging survival.
  • In consideration of the size of the patient population with incompletely treated or non-benign meningiomas, there are opportunities for conducting high quality, prospective, multicenter clinical trials.
  • [MeSH-major] Biomedical Research. Meningeal Neoplasms / pathology. Meningioma / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20835750.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


92. Shuto T, Inomori S, Fujino H, Nagano H, Hasegawa N, Kakuta Y: Cyst formation following gamma knife surgery for intracranial meningioma. J Neurosurg; 2005 Jan;102 Suppl:134-9
MedlinePlus Health Information. consumer health - Brain Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyst formation following gamma knife surgery for intracranial meningioma.
  • OBJECT: The authors conducted a study to evaluate the clinical significance of cyst formation or enlargement after gamma knife surgery (GKS) for intracranial benign meningiomas.
  • METHODS: The medical records of 160 patients with 184 tumors were examined for those with follow-up data of more than 2 years among 270 patients who underwent GKS for intracranial meningiomas between February 1992 and November 2001.
  • CONCLUSIONS: New cyst formation following GKS for benign intracranial meningioma is relatively rare; however, both preexisting and newly developed cysts tend to enlarge after GKS and often require surgery.
  • [MeSH-major] Brain Diseases / etiology. Brain Diseases / surgery. Cysts / etiology. Cysts / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Postoperative Complications. Radiosurgery / instrumentation

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15662796.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Mosqueda-Taylor A, Domínguez-Malagon H, Cano-Valdez AM, Montiel-Hernandez AM: Primary extracranial meningioma of the mandible. Med Oral Patol Oral Cir Bucal; 2009 Apr;14(4):E167-70
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary extracranial meningioma of the mandible.
  • Meningiomas are benign tumors of mesodermal origin that arise from arachnoid cell clusters that penetrate the dura to form arachnoid villi.
  • Extracranial meningiomas (EM) comprise only 2% of all meningiomas, and only six cases of primary EM of the jawbones have been described to date.
  • They may arise as an extension of intracranial meningiomas or as primary tumors and may be clinically indistinguishable from other benign tumours of the jaws, as they usually present as a well-delineated unencapsulated tumors.
  • [MeSH-major] Mandibular Neoplasms. Meningioma

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19333184.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 16
  •  go-up   go-down


94. Khong SY, Leach J, Greenwood C: Meningioma mimicking puerperal psychosis. Obstet Gynecol; 2007 Feb;109(2 Pt2):515-6
MedlinePlus Health Information. consumer health - Psychotic Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningioma mimicking puerperal psychosis.
  • BACKGROUND: Meningiomas are slow-growing benign brain tumors.
  • Meningioma was diagnosed by computed tomography and treated successfully with steroids, anticonvulsant, and craniotomy.
  • CONCLUSION: It is imperative to perform a thorough neurologic examination in a patient who presents with atypical psychiatric symptoms in the antenatal or postpartum period.
  • Neuroimaging should be performed in the presence of any neurologic abnormality to exclude intracranial lesions such as meningioma.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Psychotic Disorders / etiology. Puerperal Disorders / diagnosis

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Postpartum Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17267878.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Utsuki S, Oka H, Sato Y, Kawano N, Tsuchiya B, Kobayashi I, Fujii K: Invasive meningioma is associated with a low expression of E-cadherin and beta-catenin. Clin Neuropathol; 2005 Jan-Feb;24(1):8-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive meningioma is associated with a low expression of E-cadherin and beta-catenin.
  • Invasive meningioma shows benign histological features (WHO grade 1) and the brain expansion at the tumor-brain interface, and recurs more frequently than common meningiomas.
  • To determine the mechanism of brain expansion, we studied the relationship between invasive meningioma and cell adhesion molecules.
  • Immunostaining for E-cadherin (E-CH), N-cadherin (N-CH), beta-catenin, and Ki-67 was performed in 103 meningiomas that consisted of 61 meningothelial meningiomas, 25 fibrous meningiomas, 12 invasive meningiomas and 5 anaplastic meningiomas.
  • All the 61 meningothelial meningiomas, 10 of 12 invasive meningiomas, and 3 of 5 anaplastic meningiomas were positive for both E-CH and beta-catenin, while these were both negative in all of the fibrous meningiomas.
  • In invasive meningiomas, the expansive part of the tumor showed a lower rate (4/12 tumors) of E-CH and beta-catenin positivity, while the central part showed a higher rate (10/12 tumors).
  • The Ki-67 labeling index was higher in invasive and anaplastic meningiomas than in meningothelial meningiomas.
  • These results suggest that a reduction in cell adhesion molecules and increased proliferative activity may be related, which may lead to a better understanding of the mechanism of meningioma expansion in the future.
  • [MeSH-major] Cadherins / metabolism. Cytoskeletal Proteins / metabolism. Meningeal Neoplasms / metabolism. Meningeal Neoplasms / pathology. Meningioma / metabolism. Meningioma / pathology. Trans-Activators / metabolism

  • Genetic Alliance. consumer health - Meningioma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15696778.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / Cadherins; 0 / Cytoskeletal Proteins; 0 / Ki-67 Antigen; 0 / Trans-Activators; 0 / beta Catenin
  •  go-up   go-down


96. Mittal A, Layton KF, Finn SS, Snipes GJ, Opatowsky MJ: Cystic meningioma: unusual imaging appearance of a common intracranial tumor. Proc (Bayl Univ Med Cent); 2010 Oct;23(4):429-31

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystic meningioma: unusual imaging appearance of a common intracranial tumor.
  • Meningiomas are common tumors of the central nervous system that account for approximately 15% of all intracranial tumors and are the most common extra-axial neoplasm.
  • Most meningiomas are benign, although atypical and malignant meningiomas also exist.
  • We present a case of a woman who presented with a history of multiple recent falls, decreased energy, and increased somnolence and was found to have a "cystic meningioma."

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurol India. 2000 Dec;48(4):338-42 [11146597.001]
  • [Cites] Arq Neuropsiquiatr. 2001 Dec;59(4):939-43 [11733842.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1985 Jul;48(7):716-8 [4031920.001]
  • [Cites] Radiographics. 1991 Nov;11(6):1087-106 [1749851.001]
  • [Cites] AJNR Am J Neuroradiol. 1987 Jan-Feb;8(1):127-30 [3101455.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • (PMID = 21240328.001).
  • [ISSN] 1525-3252
  • [Journal-full-title] Proceedings (Baylor University. Medical Center)
  • [ISO-abbreviation] Proc (Bayl Univ Med Cent)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2943459
  •  go-up   go-down


97. Trinkaus M, Vranic A, Dolenc VV, Lah TT: Cathepsins B and L and their inhibitors stefin B and cystatin C as markers for malignant progression of benign meningiomas. Int J Biol Markers; 2005 Jan-Mar;20(1):50-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cathepsins B and L and their inhibitors stefin B and cystatin C as markers for malignant progression of benign meningiomas.
  • Meningiomas are, in general, slowly growing benign tumors attached to the dura mater and composed of neoplastic meningothelial (arachnoidal) cells.
  • They have a wide range of histopathological appearances and are classified, according to the aggressiveness of their growth and the risk of recurrence, as WHO grade I (benign) meningiomas, WHO grade II (atypical) meningiomas and WHO grade III anaplastic (malignant) meningiomas.
  • As invasion of normal tissue may occur in all grades, independent biological markers are needed to identify the more aggressive and recurrent meningiomas.
  • The lysosomal cysteine proteinases, cathepsins B and L, have been associated with tumor invasiveness and the aim of this study was therefore to evaluate them, together with their endogenous inhibitors stefin B and cystatin C, as potential markers for the aggressiveness of meningiomas.
  • The expression of cathepsins B and L and their inhibitors stefin B and cystatin C in 21 benign (grade I) and 9 atypical (grade II) meningiomas has been compared by immunohistochemical staining, QRT-PCR and Northern blot analysis.
  • The protein levels of cathepsins B (p=0.050) and L (p=0.019) were found to be significantly higher in atypical than in benign meningiomas.
  • Protein and mRNA levels of stefin B (p= 0.007), but not cystatin C, were significantly lower in atypical compared with benign meningiomas.
  • The expression of cathepsins and inhibitors was not different between central and peripheral meningioma tissue or between histological subtypes of meningiomas, with the exception of cathepsin L, the level of which was significantly lower in transitional meningiomas.
  • We conclude that higher protein levels of cathepsins B and L and lower mRNA levels of stefin B are potential diagnostic markers for invasive and aggressive behavior of meningiomas.
  • The diagnostic and prognostic value for relapse of meningioma needs to be confirmed in a larger population of patients.
  • [MeSH-major] Cathepsin B / metabolism. Cathepsins / metabolism. Cystatins / genetics. Cysteine Endopeptidases / metabolism. Meningeal Neoplasms / pathology. Meningioma / metabolism. Meningioma / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15832773.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CST3 protein, human; 0 / CSTB protein, human; 0 / Cystatin C; 0 / Cystatins; 0 / RNA, Messenger; 0 / Receptors, Progesterone; 88844-95-5 / Cystatin B; EC 3.4.- / Cathepsins; EC 3.4.22.- / Cysteine Endopeptidases; EC 3.4.22.1 / Cathepsin B; EC 3.4.22.15 / CTSL1 protein, human; EC 3.4.22.15 / Cathepsin L
  •  go-up   go-down


98. Teo M, Zrinzo L, King A, Aspoas AR, David KM: Giant extradural sacral meningioma. Acta Neurochir (Wien); 2010 Mar;152(3):485-8
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant extradural sacral meningioma.
  • We present the first case of primary benign fibrous meningioma restricted to the sacrum with no sign of recurrence after a long follow-up duration.
  • This occurred in a 36-year-old man who initially presented with a 3-month history of right-sided sciatica.
  • [MeSH-major] Epidural Space / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology. Sacrum / pathology. Spinal Canal / pathology. Spinal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19479187.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


99. Moradi A, Semnani V, Djam H, Tajodini A, Zali AR, Ghaemi K, Nikzad N, Madani-Civi M: Pathodiagnostic parameters for meningioma grading. J Clin Neurosci; 2008 Dec;15(12):1370-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathodiagnostic parameters for meningioma grading.
  • Meningiomas are usually slow-growing benign tumors, for which complete removal can be difficult and recurrence is an issue.
  • In this study the relationship between pathodiagnostic parameters, histological grade, and MIB-1 monoclonal antibody expression in meningioma diagnosed over 10 years in Shohada Hospital, Tehran, was assessed.
  • All cases were re-evaluated according to the latest World Health Organization (WHO) Classification.
  • Between January 1997 and December 2006, a total of 4885 intracranial tumors were diagnosed at Shohada Hospital, 378 (7.74%) of which were meningiomas.
  • All slides stained with hematoxylin and eosin were reviewed by two independent pathologists and all the diagnoses reconfirmed; histological anaplasia was classified according to the grading of the WHO Working Group 2000 as benign (Grade I), atypical with incipient signs of anaplasia (Grade II), or overtly anaplastic (Grade III).
  • The mean age of patients with meningiomas was 49.11+/-12.99 years (range 6-78 years, median=50); females outnumbered males by a ratio of 1.7 to 1.
  • Convexity meningiomas were most common, followed by meningiomas of the sphenoid ridge and cerebellopontine angle.
  • Histopathological study of completely resected meningiomas showed that loss of architecture, frequent mitotic figures, a high cellularity, increased nucleo-cytoplasmic ratio, a prominent nucleolus, brain invasion, and necrosis were correlated with the grade of the meningiomas.
  • Overall, the mitotic count was the most important marker for tumor grade.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningioma / diagnosis

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18819804.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] EC 6.3.2.19 / MIB1 ligase, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


100. Agar NY, Malcolm JG, Mohan V, Yang HW, Johnson MD, Tannenbaum A, Agar JN, Black PM: Imaging of meningioma progression by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Anal Chem; 2010 Apr 1;82(7):2621-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging of meningioma progression by matrix-assisted laser desorption ionization time-of-flight mass spectrometry.
  • Often considered benign, meningiomas represent 32% of intracranial tumors with three grades of malignancy defined by the World Health Organization (WHO) histology based classification.
  • Malignant meningiomas are associated with less than 2 years median survival.
  • The inability to predict recurrence and progression of meningiomas induces significant anxiety for patients and limits physicians in implementing prophylactic treatment approaches.
  • Five recurrent and progressive meningiomas for which surgical specimens were available from the original and progressed grades were selected and tested against nonprogressive high-grade meningiomas, high-grade gliomas, and nontumor brain specimens.
  • A preliminary classifier based on the support vector machine showed the ability to distinguish meningioma image spectra from the nontumor brain and from gliomas, a different type of brain tumor, and to enable class imaging of surgical tissue.

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2001 Apr;7(4):493-6 [11283679.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18126-31 [18776051.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):981-7 [14871976.001]
  • [Cites] Anal Chem. 2004 Feb 15;76(4):1145-55 [14961749.001]
  • [Cites] J Proteome Res. 2004 Mar-Apr;3(2):245-52 [15113100.001]
  • [Cites] Am J Pathol. 2004 Oct;165(4):1057-68 [15466373.001]
  • [Cites] Anal Chem. 1997 Dec 1;69(23):4751-60 [9406525.001]
  • [Cites] J Am Soc Mass Spectrom. 1999 Jan;10(1):67-71 [9888186.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9093-100 [15604278.001]
  • [Cites] Neuropathol Appl Neurobiol. 2005 Apr;31(2):141-9 [15771707.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):394-401 [15677390.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7674-81 [16140934.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6550-7 [16166432.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7843-8 [16912155.001]
  • [Cites] Mol Cell Proteomics. 2006 Oct;5(10):1720-6 [16546995.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Anal Chem. 2007 Oct 1;79(19):7416-23 [17822313.001]
  • [Cites] J Cell Mol Med. 2008 Sep-Oct;12(5A):1535-47 [18266982.001]
  • [Cites] Int J Cancer. 2003 May 10;104(6):728-34 [12640680.001]
  • (PMID = 20196536.001).
  • [ISSN] 1520-6882
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / U41 RR019703; United States / NIBIB NIH HHS / EB / U54 EB005149-030003; United States / NIBIB NIH HHS / EB / U54 EB005149; United States / NCRR NIH HHS / RR / P41 RR-13218; United States / NCRR NIH HHS / RR / RR013218-108435; United States / NCRR NIH HHS / RR / P41 RR013218-108435; United States / NCRR NIH HHS / RR / P41 RR013218; United States / NIBIB NIH HHS / EB / EB005149-030003
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS184740; NLM/ PMC2852177
  •  go-up   go-down






Advertisement